MDXG NASDAQ
MiMedx Group, Inc.
1W: -12.1%
1M: -17.6%
3M: -11.7%
YTD: -40.6%
1Y: -42.0%
3Y: -36.8%
5Y: -44.5%
$3.90
+0.05 (+1.30%)
After Hours: $3.87 (-0.03, -0.77%)
Weekly Expected Move ±7.5%
$3
$4
$4
$4
$4
Credit Risk of going bust: lower than 90% of companies Debt: 0.3% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.00 (down more than 99.9%), MiMedx Group, Inc. would be worth roughly what it owes.
Total debt $1.5M against a stock market value of $561.2M.
Distance to default 13.94 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $1.5M (short-term plus half of long-term), stock volatility 42.3%; Altman Z'' 6.88. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.00 (down more than 99.9%), MiMedx Group, Inc. would be worth roughly what it owes.
Total debt $1.5M against a stock market value of $561.2M.
Distance to default 13.94 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $1.5M (short-term plus half of long-term), stock volatility 42.3%; Altman Z'' 6.88. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
#289
of 1061
Biotechnology
Technical Signal Map
95 Bullish
18 Neutral
209 Bearish
MDXG
$570M
MiMedx Group, Inc.
BEARISH
-78
CAI
$9.1B
Caris Life Sciences, Inc.
BULLISH
+100
MANE
$5.8B
Veradermics, Incorporated
BULLISH
+100
BVNRY
$2.9B
Bavarian Nordic A/S
BULLISH
+100
NRIX
$2.8B
Nurix Therapeutics, Inc.
BULLISH
+100
FTRE
$2.2B
Fortrea Holdings Inc.
BULLISH
+100
AGIO
$2.2B
Agios Pharmaceuticals, Inc.
BULLISH
+100
LKFT
$2.1B
Lakefront Biotherapeutics N.V.
BULLISH
+100
SEPN
$1.9B
Septerna Inc
BULLISH
+100
COAG
$1.6B
Hemab Therapeutics Holdings, Inc. Common Stock
BULLISH
+100
VSTM
$910M
Verastem, Inc.
BULLISH
+100
SOLTF
$770M
Nxera Pharma Co., Ltd.
BULLISH
+100
ARQT
$3.9B
Arcutis Biotherapeutics, Inc.
BULLISH
+91
VCEL
$2.2B
Vericel Corporation
BULLISH
+91
MRVI
$2.1B
Maravai LifeSciences Holdings, Inc.
BULLISH
+91
KLRA
$1.7B
Kailera Therapeutics, Inc.
BULLISH
+91
SPTX
$1.1B
Seaport Therapeutics, Inc. Common Stock
BULLISH
+91
SGP
$950M
SpyGlass Pharma, Inc. Common Stock
BULLISH
+91
ENTX
$510M
Entera Bio Ltd.
BULLISH
+91
VRDN
$2.5B
Viridian Therapeutics, Inc.
BULLISH
+87
ADMA
$2.4B
ADMA Biologics, Inc.
BULLISH
+87
PRME
$670M
Prime Medicine, Inc.
BULLISH
+87
XFOR
$320M
X4 Pharmaceuticals, Inc.
BULLISH
+87
KYMR
$9.1B
Kymera Therapeutics, Inc.
BULLISH
+84
LEGN
$3.6B
Legend Biotech Corporation
BULLISH
+84
INDP
$360M
Indaptus Therapeutics, Inc.
BULLISH
+84
VIR
$1.8B
Vir Biotechnology, Inc.
BULLISH
+82
MAZE
$1.7B
Maze Therapeutics, Inc.
BULLISH
+78
SYRE
$8.3B
Spyre Therapeutics, Inc.
BULLISH
+75
TGTX
$8.3B
TG Therapeutics, Inc.
BULLISH
+75
ORKA
$5.3B
Oruka Therapeutics, Inc.
BULLISH
+75
IRON
$2.9B
Disc Medicine, Inc.
BULLISH
+75
BHVN
$2.1B
Biohaven Ltd.
BULLISH
+75
ZYME
$2.0B
Zymeworks Inc.
BULLISH
+75
LBRX
$1.2B
LB Pharmaceuticals Inc Common Stock
BULLISH
+75
OABIW
$1.1B
OmniAb, Inc.
BULLISH
+75
RIGL
$900M
Rigel Pharmaceuticals, Inc.
BULLISH
+75
ONTTF
$2.7B
Oxford Nanopore Technologies plc
BULLISH
+74
LYEL
$230M
Lyell Immunopharma, Inc.
BULLISH
+73
NAUT
$410M
Nautilus Biotechnolgy, Inc.
BULLISH
+69
ERAS
$5.0B
Erasca, Inc.
BULLISH
+68
RARE
$1.5B
Ultragenyx Pharmaceutical Inc.
BULLISH
+68
LGND
$6.0B
Ligand Pharmaceuticals Incorporated
BULLISH
+66
AUPH
$2.2B
Aurinia Pharmaceuticals Inc.
BULLISH
+66
XNCR
$1.9B
Xencor, Inc.
BULLISH
+66
TRAX
$1.6B
First Tracks Biotherapeutics Inc
BULLISH
+66
SLN
$930M
Silence Therapeutics plc
BULLISH
+66
PBYI
$570M
Puma Biotechnology, Inc.
BULLISH
+66
SGMT
$310M
Sagimet Biosciences Inc.
BULLISH
+66
NBTX
$1.5B
Nanobiotix S.A.
BULLISH
+62
SLS
$2.3B
SELLAS Life Sciences Group, Inc.
BULLISH
+59
NTLA
$1.6B
Intellia Therapeutics, Inc.
BULLISH
+59
PHAR
$710M
Pharming Group N.V.
BULLISH
+59
IOVA
$6.4B
Iovance Biotherapeutics, Inc.
BULLISH
+58
KOD
$5.5B
Kodiak Sciences Inc.
BULLISH
+58
AKBLF
$7.4B
ALK-Abelló A/S
BULLISH
+53
CASBF
$1.4B
CanSino Biologics Inc.
BULLISH
+52
REPL
$1.1B
Replimune Group, Inc.
BULLISH
+52
ABSI
$1.6B
Absci Corporation
BULLISH
+50
CRMD
$610M
CorMedix Inc.
BULLISH
+50
XERS
$1.9B
Xeris Biopharma Holdings, Inc.
BULLISH
+49
VOR
$990M
Vor Biopharma Inc.
BULLISH
+43
ALEC
$200M
Alector, Inc.
BULLISH
+43
RXRX
$2.0B
Recursion Pharmaceuticals, Inc.
BULLISH
+42
KROS
$220M
Keros Therapeutics, Inc.
BULLISH
+42
IMCR
$1.6B
Immunocore Holdings plc
BULLISH
+41
DMAC
$470M
DiaMedica Therapeutics Inc.
BULLISH
+41
DMRA
$1.3B
Damora Therapeutics, Inc.
BULLISH
+40
MLTX
$1.0B
MoonLake Immunotherapeutics
BULLISH
+40
COGT
$5.4B
Cogent Biosciences, Inc.
BULLISH
+36
ALMR
$2.1B
Alamar Biosciences, Inc.
BULLISH
+35
RLAY
$4.0B
Relay Therapeutics, Inc.
BULLISH
+34
EDIT
$370M
Editas Medicine, Inc.
BULLISH
+34
DYN
$2.9B
Dyne Therapeutics, Inc.
BULLISH
+33
PTGX
$9.0B
Protagonist Therapeutics, Inc.
LEAN BULL
+27
DFTX
$4.8B
Definium Therapeutics, Inc.
LEAN BULL
+27
NGNE
$370M
Neurogene Inc.
LEAN BULL
+27
BCYC
$250M
Bicycle Therapeutics plc
LEAN BULL
+27
LCTX
$250M
Lineage Cell Therapeutics, Inc.
LEAN BULL
+27
PTCHF
$390M
PureTech Health plc
LEAN BULL
+26
OBIO
$340M
Orchestra BioMed Holdings, Inc.
LEAN BULL
+26
ELVN
$3.0B
Enliven Therapeutics, Inc.
LEAN BULL
+18
PHVS
$2.2B
Pharvaris N.V.
LEAN BULL
+18
STOK
$1.6B
Stoke Therapeutics, Inc.
LEAN BULL
+18
CCCC
$380M
C4 Therapeutics, Inc.
LEAN BULL
+18
ZURA
$320M
Zura Bio Limited
LEAN BULL
+18
PRLD
$210M
Prelude Therapeutics Incorporated
LEAN BULL
+16
BRVE
$1.5B
Braveheart Bio, Inc.
LEAN BULL
+15
SRZN
$190M
Surrozen, Inc.
LEAN BULL
+15
CYDY
$380M
CytoDyn Inc.
LEAN BULL
+13
PVLA
$1.8B
Palvella Therapeutics, Inc.
LEAN BULL
+11
TYRA
$1.2B
Tyra Biosciences, Inc.
LEAN BULL
+11
PRTA
$420M
Prothena Corporation plc
LEAN BULL
+11
ENTA
$340M
Enanta Pharmaceuticals, Inc.
LEAN BULL
+11
GLSI
$240M
Greenwich LifeSciences, Inc.
LEAN BULL
+11
BEAM
$2.5B
Beam Therapeutics Inc.
LEAN BULL
+10
SRPT
$1.9B
Sarepta Therapeutics, Inc.
NEUTRAL
+9
ANAB
$1.5B
AnaptysBio, Inc.
NEUTRAL
+8
BCHMF
$6.8B
Bachem Holding AG
NEUTRAL
+2
SABS
$260M
SAB Biotherapeutics, Inc.
NEUTRAL
+2
NWBO
$260M
Northwest Biotherapeutics, Inc.
NEUTRAL
+2
TXG
$9.3B
10x Genomics, Inc.
NEUTRAL
+1
ABCL
$3.8B
AbCellera Biologics Inc.
NEUTRAL
+1
LYCA
$1.6B
Lycia Therapeutics Inc.
N/A
0
CTY
$200M
City Therapeutics Inc.
N/A
0
JANX
$1.0B
Janux Therapeutics, Inc.
NEUTRAL
-1
ODTX
$940M
Odyssey Therapeutics, Inc.
NEUTRAL
-2
DRUG
$520M
Bright Minds Biosciences Inc.
NEUTRAL
-2
PHMMF
$1.6B
Pharma Mar, S.A.
NEUTRAL
-3
ADPT
$4.1B
Adaptive Biotechnologies Corporation
NEUTRAL
-7
ZLAB
$2.7B
Zai Lab Limited
NEUTRAL
-8
ZBIO
$1.8B
Zenas BioPharma, Inc.
NEUTRAL
-8
VCRE
$260M
Vicore Pharma Holding AB
NEUTRAL
-8
RYTM
$6.2B
Rhythm Pharmaceuticals, Inc.
NEUTRAL
-9
GLPGF
$2.1B
Lakefront Biotherapeutics
LEAN BEAR
-12
INRLF
$640M
Valneva SE
LEAN BEAR
-12
EWTX
$4.2B
Edgewise Therapeutics, Inc.
LEAN BEAR
-16
SLGL
$230M
Sol-Gel Technologies Ltd.
LEAN BEAR
-17
SRRK
$5.0B
Scholar Rock Holding Corporation
LEAN BEAR
-18
ACAD
$3.4B
Acadia Pharmaceuticals Inc.
LEAN BEAR
-18
JBIO
$930M
Jade Biosciences, Inc.
LEAN BEAR
-18
CGEM
$880M
Cullinan Therapeutics, Inc.
LEAN BEAR
-18
ACRS
$550M
Aclaris Therapeutics, Inc.
LEAN BEAR
-18
IFRX
$230M
InflaRx N.V.
LEAN BEAR
-18
HNGZY
$6.9B
Hangzhou Tigermed Consulting Co., Ltd
LEAN BEAR
-20
SHJBF
$4.8B
Shanghai Junshi Biosciences Co., Ltd.
LEAN BEAR
-20
ADRX
$1.9B
ADARx Pharmaceuticals, Inc.
LEAN BEAR
-20
HSTC
$210M
HST Global, Inc.
LEAN BEAR
-21
MIRM
$5.2B
Mirum Pharmaceuticals, Inc.
LEAN BEAR
-22
CELC
$3.2B
Celcuity Inc.
LEAN BEAR
-22
DBVT
$230M
DBV Technologies S.A.
LEAN BEAR
-22
FENC
$350M
Fennec Pharmaceuticals Inc.
LEAN BEAR
-23
TWST
$9.2B
Twist Bioscience Corporation
LEAN BEAR
-24
INBX
$1.4B
Inhibrx Biosciences Inc.
LEAN BEAR
-24
KARD
$1.1B
Kardigan, Inc.
LEAN BEAR
-24
YDES
$350M
YD Bio Limited Ordinary Shares
LEAN BEAR
-24
FATE
$250M
Fate Therapeutics, Inc.
LEAN BEAR
-24
FGHQF
$360M
Frontage Holdings Corporation
LEAN BEAR
-25
GWIN
$360M
Glorywin Entertainment Group, Inc.
LEAN BEAR
-25
NURPF
$1.8B
Neuren Pharmaceuticals Limited
LEAN BEAR
-26
IMNM
$2.1B
Immunome, Inc.
LEAN BEAR
-27
XENE
$3.4B
Xenon Pharmaceuticals Inc.
BEARISH
-31
TSHA
$1.3B
Taysha Gene Therapies, Inc.
BEARISH
-31
ARVN
$470M
Arvinas, Inc.
BEARISH
-31
CAMP
$210M
CAMP4 Therapeutics Corporation
BEARISH
-31
SNBIF
$1.3B
SanBio Company Limited
BEARISH
-33
OVID
$420M
Ovid Therapeutics Inc.
BEARISH
-33
RZLT
$370M
Rezolute, Inc.
BEARISH
-33
TNGX
$3.9B
Tango Therapeutics, Inc.
BEARISH
-34
TRVI
$1.8B
Trevi Therapeutics, Inc.
BEARISH
-34
QURE
$1.6B
uniQure N.V.
BEARISH
-34
BPMUF
$960M
Basilea Pharmaceutica AG
BEARISH
-34
DNA
$670M
Ginkgo Bioworks Holdings, Inc.
BEARISH
-34
RAPP
$1.2B
Rapport Therapeutics, Inc. Common Stock
BEARISH
-35
MEOBF
$2.0B
Mesoblast Limited
BEARISH
-37
PRAX
$7.1B
Praxis Precision Medicines, Inc.
BEARISH
-40
CLDX
$2.3B
Celldex Therapeutics, Inc.
BEARISH
-40
BCRX
$1.9B
BioCryst Pharmaceuticals, Inc.
BEARISH
-40
APMD
$790M
Apnimed, Inc.
BEARISH
-40
STTK
$550M
Shattuck Labs, Inc.
BEARISH
-40
BNTC
$300M
Benitec Biopharma Inc.
BEARISH
-40
ELDN
$190M
Eledon Pharmaceuticals, Inc.
BEARISH
-40
PPTDF
$870M
PeptiDream Inc.
BEARISH
-41
CSPHF
$1.4B
CStone Pharmaceuticals
BEARISH
-42
DRTSW
$1.2B
Alpha Tau Medical Ltd.
BEARISH
-42
HNSBF
$330M
Hansa Biopharma AB (publ)
BEARISH
-44
VOGX
$260M
Vogenx Inc.
BEARISH
-45
PCVX
$9.5B
Vaxcyte, Inc.
BEARISH
-47
IDRSF
$1.4B
Idorsia Ltd
BEARISH
-47
VBIZF
$400M
Viva Biotech Holdings
BEARISH
-47
RCKT
$250M
Rocket Pharmaceuticals, Inc.
BEARISH
-47
DNLI
$2.9B
Denali Therapeutics Inc.
BEARISH
-48
CRVS
$890M
Corvus Pharmaceuticals, Inc.
BEARISH
-48
SVRA
$870M
Savara Inc.
BEARISH
-48
IMRX
$240M
Immuneering Corporation
BEARISH
-48
ARWR
$8.2B
Arrowhead Pharmaceuticals, Inc.
BEARISH
-49
IONS
$7.1B
Ionis Pharmaceuticals, Inc.
BEARISH
-49
PTCT
$5.1B
PTC Therapeutics, Inc.
BEARISH
-49
AMLX
$3.4B
Amylyx Pharmaceuticals, Inc.
BEARISH
-49
MBX
$2.3B
MBX Biosciences, Inc. Common Stock
BEARISH
-49
VERA
$2.0B
Vera Therapeutics, Inc.
BEARISH
-49
IMTX
$1.1B
Immatics N.V.
BEARISH
-49
KURA
$850M
Kura Oncology, Inc.
BEARISH
-49
ATTO
$630M
Attovia Therapeutics, Inc.
BEARISH
-49
OCS
$490M
Oculis Holding AG
BEARISH
-49
AURA
$650M
Aura Biosciences, Inc.
BEARISH
-50
TTRX
$310M
Turn Therapeutics Inc.
BEARISH
-50
ARCT
$280M
Arcturus Therapeutics Holdings Inc.
BEARISH
-50
SPHRY
$220M
Starpharma Holdings Limited
BEARISH
-50
DNTH
$4.3B
Dianthus Therapeutics, Inc.
BEARISH
-52
GHRS
$1.2B
GH Research PLC
BEARISH
-52
ABUS
$830M
Arbutus Biopharma Corp
BEARISH
-52
QTTB
$260M
Q32 Bio Inc.
BEARISH
-52
GNNSF
$9.6B
Genscript Biotech Corporation
BEARISH
-53
ANL
$560M
Adlai Nortye Ltd.
BEARISH
-53
ARTV
$300M
Artiva Biotherapeutics, Inc.
BEARISH
-53
PLX
$210M
Protalix BioTherapeutics, Inc.
BEARISH
-53
CGON
$5.5B
CG Oncology Inc.
BEARISH
-58
CRSP
$4.8B
CRISPR Therapeutics AG
BEARISH
-58
PBLS
$3.0B
Parabilis Medicines, Inc.
BEARISH
-58
MLYS
$1.8B
Mineralys Therapeutics, Inc.
BEARISH
-58
GENB
$1.6B
Generate Biomedicines, Inc.
BEARISH
-58
CMPS
$1.6B
COMPASS Pathways plc
BEARISH
-58
NKTR
$1.1B
Nektar Therapeutics
BEARISH
-58
AVBP
$1.0B
ArriVent BioPharma, Inc.
BEARISH
-58
ALMS
$880M
Alumis Inc.
BEARISH
-58
SANA
$700M
Sana Biotechnology, Inc.
BEARISH
-58
FULC
$280M
Fulcrum Therapeutics, Inc.
BEARISH
-58
IPSC
$260M
Century Therapeutics, Inc.
BEARISH
-58
CAMRF
$3.7B
Camurus AB
BEARISH
-59
ORIC
$1.4B
ORIC Pharmaceuticals, Inc.
BEARISH
-59
IMVT
$5.9B
Immunovant, Inc.
BEARISH
-60
HRMY
$2.1B
Harmony Biosciences Holdings, Inc.
BEARISH
-60
ANRO
$860M
Alto Neuroscience, Inc.
BEARISH
-60
DSGN
$640M
Design Therapeutics, Inc.
BEARISH
-60
RCUS
$2.3B
Arcus Biosciences, Inc.
BEARISH
-62
AUTL
$410M
Autolus Therapeutics plc
BEARISH
-62
AVLN
$1.1B
Avalyn Pharma Inc. Common Stock
BEARISH
-65
BCAX
$1.1B
Bicara Therapeutics Inc. Common Stock
BEARISH
-65
MNKD
$1.0B
MannKind Corporation
BEARISH
-65
GLUE
$920M
Monte Rosa Therapeutics, Inc.
BEARISH
-65
WVE
$630M
Wave Life Sciences Ltd.
BEARISH
-65
LRMR
$240M
Larimar Therapeutics, Inc.
BEARISH
-65
KRYS
$9.2B
Krystal Biotech, Inc.
BEARISH
-66
INVA
$1.5B
Innoviva, Inc.
BEARISH
-66
ACHV
$670M
Achieve Life Sciences, Inc.
BEARISH
-66
TECX
$390M
Tectonic Therapeutic, Inc.
BEARISH
-66
EIKN
$390M
Eikon Therapeutics, Inc. Common Stock
BEARISH
-66
CLVLF
$250M
Clinuvel Pharmaceuticals Limited
BEARISH
-66
RNAC
$190M
Cartesian Therapeutics, Inc.
BEARISH
-66
NAGE
$190M
Niagen Bioscience Inc
BEARISH
-66
IBRX
$8.7B
ImmunityBio, Inc.
BEARISH
-69
DRTS
$1.2B
Alpha Tau Medical Ltd
BEARISH
-69
SLDB
$630M
Solid Biosciences Inc.
BEARISH
-69
NWPHF
$410M
Newron Pharmaceuticals S.p.A.
BEARISH
-71
OLMA
$560M
Olema Pharmaceuticals, Inc.
BEARISH
-74
CBIO
$480M
Crescent Biopharma, Inc.
BEARISH
-74
BLSM
$430M
BlossomHill Therapeutics, Inc.
BEARISH
-74
TARS
$3.2B
Tarsus Pharmaceuticals, Inc.
BEARISH
-75
AAPG
$1.4B
Ascentage Pharma Group International
BEARISH
-75
OMER
$1.2B
Omeros Corporation
BEARISH
-75
ASCLF
$770M
Ascletis Pharma Inc.
BEARISH
-75
NVCT
$650M
Nuvectis Pharma, Inc.
BEARISH
-75
FDMT
$600M
4D Molecular Therapeutics, Inc.
BEARISH
-75
PHAT
$460M
Phathom Pharmaceuticals, Inc.
BEARISH
-75
EPRX
$450M
Eupraxia Pharmaceuticals Inc.
BEARISH
-75
AGEN
$290M
Agenus Inc.
BEARISH
-75
GALT
$210M
Galectin Therapeutics Inc.
BEARISH
-75
BLTE
$5.9B
Belite Bio, Inc
BEARISH
-78
NUVB
$1.6B
Nuvation Bio Inc.
BEARISH
-78
NVAX
$1.6B
Novavax, Inc.
BEARISH
-78
MGTX
$880M
MeiraGTx Holdings plc
BEARISH
-78
LXRX
$630M
Lexicon Pharmaceuticals, Inc.
BEARISH
-78
CLYM
$590M
Climb Bio, Inc.
BEARISH
-78
MNPR
$470M
Monopar Therapeutics Inc.
BEARISH
-78
AVIR
$320M
Atea Pharmaceuticals, Inc.
BEARISH
-78
CYTK
$8.5B
Cytokinetics, Incorporated
BEARISH
-82
NAMS
$2.3B
NewAmsterdam Pharma Company N.V.
BEARISH
-82
HBMHF
$1.3B
HBM Holdings Limited
BEARISH
-82
GERN
$720M
Geron Corporation
BEARISH
-82
SLBT
$640M
SL Science Holding Ltd
BEARISH
-82
GYRE
$620M
Gyre Therapeutics, Inc.
BEARISH
-82
ANNX
$610M
Annexon, Inc.
BEARISH
-82
AGMB
$450M
AgomAb Therapeutics N.V. American Depositary Shares
BEARISH
-82
ASMB
$400M
Assembly Biosciences, Inc.
BEARISH
-82
RLMD
$350M
Relmada Therapeutics, Inc.
BEARISH
-82
MPLT
$340M
MapLight Therapeutics, Inc.
BEARISH
-82
CTNM
$270M
Contineum Therapeutics, Inc.
BEARISH
-82
LXEO
$230M
Lexeo Therapeutics, Inc. Common Stock
BEARISH
-82
BOVNF
$220M
BioInvent International AB (publ)
BEARISH
-82
BBOT
$210M
BridgeBio Oncology Therapeutics Inc.
BEARISH
-82
IDYA
$3.4B
IDEAYA Biosciences, Inc.
BEARISH
-84
TLX
$3.1B
Telix Pharmaceuticals Limited
BEARISH
-84
PGEN
$2.2B
Precigen, Inc.
BEARISH
-84
ZVRA
$580M
Zevra Therapeutics, Inc.
BEARISH
-84
IRD
$290M
Opus Genetics, Inc.
BEARISH
-84
TVTX
$4.7B
Travere Therapeutics, Inc.
BEARISH
-87
URGN
$1.7B
UroGen Pharma Ltd.
BEARISH
-87
MDCLF
$1.1B
MedinCell S.A.
BEARISH
-87
IMMX
$680M
Immix Biopharma, Inc.
BEARISH
-87
CADL
$610M
Candel Therapeutics, Inc.
BEARISH
-87
GNFTF
$470M
Genfit S.A.
BEARISH
-87
IKT
$220M
Inhibikase Therapeutics, Inc.
BEARISH
-87
REGMF
$5.6B
RemeGen Co., Ltd.
BEARISH
-91
GENSF
$1.8B
Genus plc
BEARISH
-91
OCUL
$1.4B
Ocular Therapeutix, Inc.
BEARISH
-91
GPCR
$1.2B
Structure Therapeutics Inc.
BEARISH
-91
SNDX
$1.2B
Syndax Pharmaceuticals, Inc.
BEARISH
-91
AKTS
$850M
Aktis Oncology, Inc.
BEARISH
-91
ARDX
$770M
Ardelyx, Inc.
BEARISH
-91
CTMX
$510M
CytomX Therapeutics, Inc.
BEARISH
-91
PROK
$470M
ProKidney Corp.
BEARISH
-91
FTH
$440M
Faeth Therapeutics, Inc.
BEARISH
-91
ALLO
$430M
Allogene Therapeutics, Inc.
BEARISH
-91
AVCTF
$420M
Avacta Group Plc
BEARISH
-91
SPRY
$400M
ARS Pharmaceuticals, Inc.
BEARISH
-91
CAPR
$340M
Capricor Therapeutics, Inc.
BEARISH
-91
KYTX
$330M
Kyverna Therapeutics, Inc.
BEARISH
-91
SPHDF
$280M
Santhera Pharmaceuticals Holding AG
BEARISH
-91
ORYZF
$250M
Oryzon Genomics S.A.
BEARISH
-91
OCGN
$250M
Ocugen, Inc.
BEARISH
-91
ABEO
$250M
Abeona Therapeutics Inc.
BEARISH
-91
VNDA
$240M
Vanda Pharmaceuticals Inc.
BEARISH
-91
HLOSF
$240M
Healios K.K.
BEARISH
-91
IPHYF
$210M
Innate Pharma S.A.
BEARISH
-91
EVMN
$190M
Evommune, Inc.
BEARISH
-91
BIOA
$190M
BioAge Labs Inc.
BEARISH
-91
AXSM
$7.6B
Axsome Therapeutics, Inc.
BEARISH
-100
TRSBF
$4.3B
3SBio Inc.
BEARISH
-100
VKTX
$3.1B
Viking Therapeutics, Inc.
BEARISH
-100
BRCTF
$2.6B
BioArctic AB
BEARISH
-100
ZLDPF
$2.4B
Zealand Pharma A/S
BEARISH
-100
INCPF
$2.4B
InnoCare Pharma Limited
BEARISH
-100
IVEVF
$750M
Inventiva S.A.
BEARISH
-100
RGNX
$440M
REGENXBIO Inc.
BEARISH
-100
ALT
$410M
Altimmune, Inc.
BEARISH
-100
AVTX
$370M
Avalo Therapeutics, Inc.
BEARISH
-100
DMTRF
$310M
3-D Matrix, Ltd.
BEARISH
-100
CABA
$250M
Cabaletta Bio, Inc.
BEARISH
-100
SCTX
$250M
Scribe Therapeutics Inc.
BEARISH
-100
ACIU
$250M
AC Immune S.A.
BEARISH
-100
PALI
$230M
Palisade Bio, Inc.
BEARISH
-100
Peer Comparison
| Symbol | Mkt Cap | P/E | ROE % | ROIC % | Net Mgn % | Rev Grw % | Piotroski | Signal | 1Y Ret % |
|---|---|---|---|---|---|---|---|---|---|
| MDXG MiMedx Group, Inc. | $570M | 96.6 | 2.9 | 5.8 | -23.1 | -2.4 | 6 | BEARISH | -42.3 |
| CAI Caris Life Sciences, Inc. | $9.1B | 91.5 | 20.1 | 61.1 | -0.2 | 445.5 | 7 | BULLISH | 8.4 |
| MANE Veradermics, Incorporated | $5.8B | — | — | — | — | — | — | BULLISH | — |
| BVNRY Bavarian Nordic A/S | $2.9B | 13.0 | 12.3 | 7.1 | 36.0 | -5.8 | 7 | BULLISH | 1.9 |
| NRIX Nurix Therapeutics, Inc. | $2.8B | 10.6 | 44.0 | -1896.6 | 81.7 | 738.8 | 8 | BULLISH | 140.8 |
| FTRE Fortrea Holdings Inc. | $2.2B | -26.2 | -15.3 | 0.6 | -1.9 | -2.1 | 6 | BULLISH | 116.2 |
| AGIO Agios Pharmaceuticals, Inc. | $2.2B | -5.4 | -34.3 | -82.5 | -225.1 | 140.6 | 4 | BULLISH | -12.2 |
| LKFT Lakefront Biotherapeutics N.V. | $2.1B | — | — | — | — | — | — | BULLISH | — |
| SEPN Septerna Inc | $1.9B | -81.5 | -6.3 | -93.1 | -48.7 | 17878.5 | 5 | BULLISH | 103.7 |
| COAG Hemab Therapeutics Holdings, Inc. Common Stock | $1.6B | — | — | — | — | — | — | BULLISH | — |
| VSTM Verastem, Inc. | $910M | -4.1 | -471.2 | 6197.3 | -86.5 | 3995.7 | 4 | BULLISH | 27.0 |
| SOLTF Nxera Pharma Co., Ltd. | $770M | -15.8 | -12.0 | -1.7 | -2.6 | 7.5 | 4 | BULLISH | 38.2 |
| ARQT Arcutis Biotherapeutics, Inc. | $3.9B | 143.7 | 15.9 | 34.7 | 11.6 | 76.1 | 7 | BULLISH | 57.5 |
| VCEL Vericel Corporation | $2.2B | 90.6 | 7.2 | 5.9 | 2.8 | 23.0 | 7 | BULLISH | 19.1 |
| MRVI Maravai LifeSciences Holdings, Inc. | $2.1B | -15.3 | -32.9 | 24.4 | -24.1 | -3.3 | 5 | BULLISH | 142.2 |
| KLRA Kailera Therapeutics, Inc. | $1.7B | — | — | — | — | — | — | BULLISH | — |
| SPTX Seaport Therapeutics, Inc. Common Stock | $1.1B | — | — | — | — | — | — | BULLISH | — |
| SGP SpyGlass Pharma, Inc. Common Stock | $950M | — | — | — | — | — | — | BULLISH | — |
| ENTX Entera Bio Ltd. | $510M | -8.8 | -138.9 | 314.4 | — | -100.0 | 1 | BULLISH | 37.8 |
| VRDN Viridian Therapeutics, Inc. | $2.5B | -6.7 | -65.7 | 418.2 | -44760.2 | 23220.3 | 4 | BULLISH | 8.7 |
| ADMA ADMA Biologics, Inc. | $2.4B | 15.4 | 41.9 | 35.5 | 30.4 | 8.0 | 5 | BULLISH | -26.4 |
| PRME Prime Medicine, Inc. | $670M | -4.0 | -373.3 | -271.3 | -3649.0 | -17.9 | 3 | BULLISH | -18.4 |
| XFOR X4 Pharmaceuticals, Inc. | $320M | -2.7 | -113.1 | -281.1 | -183.5 | -51.6 | 4 | BULLISH | -14.5 |
| KYMR Kymera Therapeutics, Inc. | $9.1B | -36.7 | -24.2 | -30.7 | -94.2 | 134.8 | 6 | BULLISH | 100.8 |
| LEGN Legend Biotech Corporation | $3.6B | -42.9 | -8.1 | -8.2 | 8.6 | 59.5 | 4 | BULLISH | -32.3 |
| INDP Indaptus Therapeutics, Inc. | $360M | -0.5 | -318.0 | 6437.4 | — | — | 4 | BULLISH | -8.8 |
| VIR Vir Biotechnology, Inc. | $1.8B | -6.2 | -26.1 | -38.8 | 33.5 | 1495.9 | 5 | BULLISH | 93.5 |
| MAZE Maze Therapeutics, Inc. | $1.7B | -11.4 | -37.3 | -112.3 | — | — | 3 | BULLISH | 4.3 |
| SYRE Spyre Therapeutics, Inc. | $8.3B | -50.4 | -23.0 | 359.8 | — | — | 3 | BULLISH | 323.8 |
| TGTX TG Therapeutics, Inc. | $8.3B | 18.5 | 100.3 | 73.5 | 3.2 | 76.1 | 6 | BULLISH | 69.3 |
| ORKA Oruka Therapeutics, Inc. | $5.3B | -38.6 | -18.2 | -50.3 | — | — | 4 | BULLISH | 251.6 |
| IRON Disc Medicine, Inc. | $2.9B | -12.1 | -39.1 | 1672.3 | — | — | 1 | BULLISH | -6.7 |
| BHVN Biohaven Ltd. | $2.1B | -3.3 | -799.5 | -1083.0 | — | — | 3 | BULLISH | -7.9 |
| ZYME Zymeworks Inc. | $2.0B | -14.3 | -72.3 | -156.9 | -980.8 | -69.8 | 2 | BULLISH | 62.6 |
| LBRX LB Pharmaceuticals Inc Common Stock | $1.2B | -13.4 | -25.8 | -768.9 | — | — | 2 | BULLISH | 148.2 |
| OABIW OmniAb, Inc. | $1.1B | -13.8 | -16.9 | -16.8 | -43.7 | 66.9 | 6 | BULLISH | -17.6 |
| RIGL Rigel Pharmaceuticals, Inc. | $900M | 2.8 | 126.9 | 88.5 | 22.0 | 3.3 | 4 | BULLISH | 68.7 |
| ONTTF Oxford Nanopore Technologies plc | $2.7B | -18.0 | -25.6 | -36.2 | -41.1 | 14.4 | 4 | BULLISH | 41.7 |
| LYEL Lyell Immunopharma, Inc. | $230M | -0.6 | -93.3 | -227.7 | -1118875.0 | -55.0 | 3 | BULLISH | -42.6 |
| NAUT Nautilus Biotechnolgy, Inc. | $410M | -6.5 | -41.0 | -89.2 | -6682.1 | — | 2 | BULLISH | 136.9 |
| ERAS Erasca, Inc. | $5.0B | -15.8 | -78.2 | -87.5 | — | — | 2 | BULLISH | 539.5 |
| RARE Ultragenyx Pharmaceutical Inc. | $1.5B | -2.9 | 839.4 | -67.5 | -43.0 | 17.5 | 2 | BULLISH | -50.0 |
| LGND Ligand Pharmaceuticals Incorporated | $6.0B | 31.2 | 22.0 | 11.3 | 76.2 | 54.9 | 5 | BULLISH | 66.7 |
| AUPH Aurinia Pharmaceuticals Inc. | $2.2B | 7.3 | 66.1 | 127.2 | 45.0 | 19.8 | 7 | BULLISH | 45.1 |
| XNCR Xencor, Inc. | $1.9B | -13.7 | -29.1 | -152.4 | -42.4 | -36.1 | 2 | BULLISH | 127.0 |
| TRAX First Tracks Biotherapeutics Inc | $1.6B | — | — | — | — | — | — | BULLISH | — |
| SLN Silence Therapeutics plc | $930M | -5.2 | -90.4 | 157.8 | — | -97.6 | 1 | BULLISH | 171.0 |
| PBYI Puma Biotechnology, Inc. | $570M | 20.3 | 22.0 | 52.8 | 14.5 | -2.9 | 6 | BULLISH | 108.8 |
| SGMT Sagimet Biosciences Inc. | $310M | -8.2 | -24.4 | -231.4 | — | — | 3 | BULLISH | 14.0 |
| NBTX Nanobiotix S.A. | $1.5B | -27.5 | 104.2 | 62.0 | -626.0 | 49.1 | 4 | BULLISH | 79.8 |
| SLS SELLAS Life Sciences Group, Inc. | $2.3B | -57.2 | -39.6 | 55646.0 | — | — | 4 | BULLISH | 511.6 |
| NTLA Intellia Therapeutics, Inc. | $1.6B | -3.6 | -55.4 | -92.1 | -1392.3 | 12.6 | 5 | BULLISH | -52.0 |
| PHAR Pharming Group N.V. | $710M | 81.8 | 3.6 | 3.2 | 1.8 | 7.8 | 7 | BULLISH | -12.7 |
| IOVA Iovance Biotherapeutics, Inc. | $6.4B | -20.1 | -40.4 | -49.1 | -47.6 | 34.5 | 6 | BULLISH | 548.0 |
| KOD Kodiak Sciences Inc. | $5.5B | -21.7 | -368.4 | -630.1 | — | — | 1 | BULLISH | 388.6 |
| AKBLF ALK-Abelló A/S | $7.4B | 39.9 | 21.2 | 23.9 | 18.9 | 16.4 | 8 | BULLISH | 12.8 |
| CASBF CanSino Biologics Inc. | $1.4B | 367.7 | 0.8 | -1.2 | 11.0 | 32.5 | 7 | BULLISH | -25.5 |
| REPL Replimune Group, Inc. | $1.1B | -4.2 | -134.3 | -1055.2 | — | — | 1 | BULLISH | 48.3 |
| ABSI Absci Corporation | $1.6B | -13.4 | -57.7 | -213.1 | -10443.4 | -62.3 | 5 | BULLISH | 147.5 |
| CRMD CorMedix Inc. | $610M | 3.3 | 54.9 | 57.2 | 25.5 | 280.5 | 5 | BULLISH | -28.4 |
| XERS Xeris Biopharma Holdings, Inc. | $1.9B | -107.0 | 118.2 | 18.3 | -33.8 | 36.3 | 6 | BULLISH | 13.5 |
| VOR Vor Biopharma Inc. | $990M | 0.1 | -73.6 | 22.2 | — | — | 3 | BULLISH | -28.1 |
| ALEC Alector, Inc. | $200M | -1.9 | -385.1 | 66.8 | -692.5 | -82.9 | 1 | BULLISH | 40.0 |
| RXRX Recursion Pharmaceuticals, Inc. | $2.0B | -3.9 | -56.6 | -99.7 | -1708.0 | -14.9 | 4 | BULLISH | -33.0 |
| KROS Keros Therapeutics, Inc. | $220M | -3.1 | -17.2 | -392.2 | — | -93.6 | 3 | BULLISH | -24.0 |
| IMCR Immunocore Holdings plc | $1.6B | -176.2 | -2.3 | -472.0 | -0.7 | 13.4 | 4 | BULLISH | -3.4 |
| DMAC DiaMedica Therapeutics Inc. | $470M | -11.9 | -114.6 | 616.3 | — | — | 2 | BULLISH | 26.3 |
| DMRA Damora Therapeutics, Inc. | $1.3B | — | — | — | — | — | — | BULLISH | — |
| MLTX MoonLake Immunotherapeutics | $1.0B | -3.1 | -67.4 | 2902.7 | — | — | 1 | BULLISH | 25.3 |
| COGT Cogent Biosciences, Inc. | $5.4B | -13.9 | -109.7 | 1964.0 | — | — | 3 | BULLISH | 111.6 |
| ALMR Alamar Biosciences, Inc. | $2.1B | — | — | — | — | — | — | BULLISH | — |
| RLAY Relay Therapeutics, Inc. | $4.0B | -12.0 | -36.8 | -2519.7 | -23916.3 | 23.9 | 4 | BULLISH | 174.6 |
| EDIT Editas Medicine, Inc. | $370M | -3.4 | -118.8 | 71.4 | -153.3 | 20.8 | 4 | BULLISH | -30.1 |
| DYN Dyne Therapeutics, Inc. | $2.9B | -5.1 | -81.6 | 240.4 | — | — | 2 | BULLISH | -1.1 |
| PTGX Protagonist Therapeutics, Inc. | $9.0B | 115.5 | 11.0 | 84.1 | 76.3 | 34.8 | 7 | LEAN BULL | 88.5 |
| DFTX Definium Therapeutics, Inc. | $4.8B | -10.8 | -25.7 | 82.4 | — | — | 2 | LEAN BULL | — |
| NGNE Neurogene Inc. | $370M | -4.9 | -45.3 | -111469.0 | — | — | 2 | LEAN BULL | -9.7 |
| BCYC Bicycle Therapeutics plc | $250M | -1.4 | -32.3 | -1197.0 | -8002.1 | 217.4 | 4 | LEAN BULL | -52.0 |
| LCTX Lineage Cell Therapeutics, Inc. | $250M | -7.3 | -59.0 | -171.3 | 138.6 | 19.9 | 5 | LEAN BULL | -39.4 |
| PTCHF PureTech Health plc | $390M | 157.1 | 0.2 | 50.8 | 1890.6 | 7.7 | 4 | LEAN BULL | -5.4 |
| OBIO Orchestra BioMed Holdings, Inc. | $340M | -5.6 | -397.3 | 468.3 | -26994.3 | 986.1 | 4 | LEAN BULL | 46.0 |
| ELVN Enliven Therapeutics, Inc. | $3.0B | -26.5 | -15.3 | -6535.0 | — | — | 3 | LEAN BULL | 112.0 |
| PHVS Pharvaris N.V. | $2.2B | -10.6 | -70.7 | 860.9 | — | — | 4 | LEAN BULL | 39.0 |
| STOK Stoke Therapeutics, Inc. | $1.6B | -7.8 | -61.1 | -318.5 | -660.8 | -86.2 | 2 | LEAN BULL | -19.1 |
| CCCC C4 Therapeutics, Inc. | $380M | -3.2 | -48.1 | -175.0 | -355.9 | 2.3 | 4 | LEAN BULL | 31.0 |
| ZURA Zura Bio Limited | $320M | -3.8 | -65.4 | 806.5 | — | — | 2 | LEAN BULL | 15.7 |
| PRLD Prelude Therapeutics Incorporated | $210M | -4.9 | -57.7 | 14236.3 | -244.1 | 220.3 | 5 | LEAN BULL | 139.5 |
| BRVE Braveheart Bio, Inc. | $1.5B | — | — | — | — | — | — | LEAN BULL | — |
| SRZN Surrozen, Inc. | $190M | -0.7 | 387.2 | 11.1 | 1003.5 | -8.8 | 2 | LEAN BULL | 114.8 |
| CYDY CytoDyn Inc. | $380M | -4.9 | 57.8 | 24.6 | — | 100.0 | 4 | LEAN BULL | -16.2 |
| PVLA Palvella Therapeutics, Inc. | $1.8B | -27.4 | -46.6 | 137.5 | — | — | 3 | LEAN BULL | 82.1 |
| TYRA Tyra Biosciences, Inc. | $1.2B | -8.9 | -45.3 | -2390.9 | — | — | 2 | LEAN BULL | 51.2 |
| PRTA Prothena Corporation plc | $420M | -10.5 | -14.4 | -871.5 | -1839.9 | 427.3 | 5 | LEAN BULL | -10.3 |
| ENTA Enanta Pharmaceuticals, Inc. | $340M | -5.0 | -70.1 | 141.5 | -135.8 | 0.7 | 4 | LEAN BULL | 15.9 |
| GLSI Greenwich LifeSciences, Inc. | $240M | -11.0 | -951.6 | 299.9 | — | — | 2 | LEAN BULL | 74.4 |
| BEAM Beam Therapeutics Inc. | $2.5B | -30.2 | -8.1 | -184.5 | -25036.3 | 158.9 | 4 | LEAN BULL | -10.9 |
| SRPT Sarepta Therapeutics, Inc. | $1.9B | -13.0 | -9.5 | -6.3 | -1.2 | -20.4 | 4 | NEUTRAL | -17.2 |
| ANAB AnaptysBio, Inc. | $1.5B | 7.3 | -1146.3 | 466.0 | 668.9 | 92.9 | 5 | NEUTRAL | 112.3 |
| BCHMF Bachem Holding AG | $6.8B | 41.9 | 10.6 | 8.2 | 15.4 | 4.3 | 3 | NEUTRAL | 24.7 |
| SABS SAB Biotherapeutics, Inc. | $260M | 0.9 | -11.3 | -48.4 | — | -100.0 | 3 | NEUTRAL | 1.3 |
| NWBO Northwest Biotherapeutics, Inc. | $260M | -6.7 | 55.8 | -188.7 | -1142.6 | 98.6 | 3 | NEUTRAL | -33.7 |
| TXG 10x Genomics, Inc. | $9.3B | -132.5 | -9.4 | -19.8 | -11.9 | -4.3 | 5 | NEUTRAL | 466.6 |
| ABCL AbCellera Biologics Inc. | $3.8B | -23.5 | -17.3 | -36.2 | -1368.6 | 101.3 | 4 | NEUTRAL | 126.7 |
| LYCA Lycia Therapeutics Inc. | $1.6B | — | — | — | — | — | — | N/A | — |
| CTY City Therapeutics Inc. | $200M | — | — | — | — | — | — | N/A | — |
| JANX Janux Therapeutics, Inc. | $1.0B | -10.4 | -10.7 | 516.9 | -214.0 | 7162.0 | 4 | NEUTRAL | -30.7 |
| ODTX Odyssey Therapeutics, Inc. | $940M | — | — | — | — | — | — | NEUTRAL | — |
| DRUG Bright Minds Biosciences Inc. | $520M | -26.2 | -13.7 | -105758.3 | — | — | 3 | NEUTRAL | -11.7 |
| PHMMF Pharma Mar, S.A. | $1.6B | 21.2 | 24.9 | 35.9 | -2.0 | 15.5 | 7 | NEUTRAL | 1.7 |
| ADPT Adaptive Biotechnologies Corporation | $4.1B | -68.5 | -39.6 | -14.1 | -55.6 | 50.1 | 5 | NEUTRAL | 60.6 |
| ZLAB Zai Lab Limited | $2.7B | -13.3 | -26.9 | -85.4 | -47.8 | 5.1 | 3 | NEUTRAL | -10.4 |
| ZBIO Zenas BioPharma, Inc. | $1.8B | -2.9 | -199.0 | 5842.1 | -11145.6 | -93.3 | 2 | NEUTRAL | 14.2 |
| VCRE Vicore Pharma Holding AB | $260M | — | — | — | — | — | — | NEUTRAL | — |
| RYTM Rhythm Pharmaceuticals, Inc. | $6.2B | -29.5 | -200.0 | 144.2 | -69.2 | 53.5 | 4 | NEUTRAL | -16.6 |
| GLPGF Lakefront Biotherapeutics | $2.1B | 3.8 | 20.2 | 39.4 | 17.4 | 259.3 | 5 | LEAN BEAR | -4.5 |
| INRLF Valneva SE | $640M | -2.8 | -118.0 | -54.8 | -89.3 | -27.2 | 1 | LEAN BEAR | -25.4 |
| EWTX Edgewise Therapeutics, Inc. | $4.2B | -21.4 | -38.0 | 1912.5 | — | — | 1 | LEAN BEAR | 160.4 |
| SLGL Sol-Gel Technologies Ltd. | $230M | -12.4 | -35.9 | -228.0 | 36.4 | 282.9 | 3 | LEAN BEAR | 74.8 |
| SRRK Scholar Rock Holding Corporation | $5.0B | -12.8 | -167.8 | 931.3 | — | — | 2 | LEAN BEAR | 43.2 |
| ACAD Acadia Pharmaceuticals Inc. | $3.4B | 9.0 | 35.7 | 63.9 | 10.2 | 11.8 | 5 | LEAN BEAR | -8.4 |
| JBIO Jade Biosciences, Inc. | $930M | -5.4 | -47.8 | 629.9 | — | — | 3 | LEAN BEAR | 47.4 |
| CGEM Cullinan Therapeutics, Inc. | $880M | -4.4 | -50.3 | 1635.6 | — | — | 1 | LEAN BEAR | 91.2 |
| ACRS Aclaris Therapeutics, Inc. | $550M | -6.6 | -59.1 | -206.5 | -1320.1 | -51.0 | 3 | LEAN BEAR | 76.3 |
| IFRX InflaRx N.V. | $230M | -3.0 | -38.5 | 251.5 | — | -106.2 | 4 | LEAN BEAR | 18.6 |
| HNGZY Hangzhou Tigermed Consulting Co., Ltd | $6.9B | 597.8 | 0.5 | 1.6 | -24.2 | 12.0 | 6 | LEAN BEAR | 11.2 |
| SHJBF Shanghai Junshi Biosciences Co., Ltd. | $4.8B | -69.3 | -7.1 | -6.3 | 4.4 | 29.7 | 5 | LEAN BEAR | -20.8 |
| ADRX ADARx Pharmaceuticals, Inc. | $1.9B | — | — | — | — | — | — | LEAN BEAR | — |
| HSTC HST Global, Inc. | $210M | -538.5 | -2.5 | -1.2 | -13.7 | 564.0 | 5 | LEAN BEAR | 349900.0 |
| MIRM Mirum Pharmaceuticals, Inc. | $5.2B | -5.9 | -703.0 | -27.3 | -38.1 | 44.0 | 3 | LEAN BEAR | 22.2 |
| CELC Celcuity Inc. | $3.2B | -16.0 | -1433.7 | 1325.2 | — | — | 3 | LEAN BEAR | -4.1 |
| DBVT DBV Technologies S.A. | $230M | -2.6 | -142.6 | -2201.5 | — | -100.0 | 2 | LEAN BEAR | -34.3 |
| FENC Fennec Pharmaceuticals Inc. | $350M | -81.5 | -18.6 | -76.2 | 11.0 | 77.8 | 6 | LEAN BEAR | 18.1 |
| TWST Twist Bioscience Corporation | $9.2B | -71.7 | -29.6 | -29.2 | -29.6 | 19.2 | 2 | LEAN BEAR | 368.6 |
| INBX Inhibrx Biosciences Inc. | $1.4B | -11.2 | -1773.6 | 55.8 | — | -100.0 | 4 | LEAN BEAR | 67.0 |
| KARD Kardigan, Inc. | $1.1B | — | — | — | — | — | — | LEAN BEAR | — |
| YDES YD Bio Limited Ordinary Shares | $350M | — | — | — | — | — | — | LEAN BEAR | -64.9 |
| FATE Fate Therapeutics, Inc. | $250M | -2.0 | -60.7 | -140.1 | -1448.6 | -23.4 | 2 | LEAN BEAR | 115.1 |
| FGHQF Frontage Holdings Corporation | $360M | 36.5 | 3.1 | 3.0 | 4.6 | 9.8 | 7 | LEAN BEAR | 16.8 |
| GWIN Glorywin Entertainment Group, Inc. | $360M | -26081.4 | 11.7 | 5.1 | — | — | 1 | LEAN BEAR | 229.5 |
| NURPF Neuren Pharmaceuticals Limited | $1.8B | 118.1 | 6.2 | 22.4 | 14.6 | -68.5 | 5 | LEAN BEAR | 20.8 |
| IMNM Immunome, Inc. | $2.1B | -7.4 | -64.0 | -2208.4 | — | -100.0 | 4 | LEAN BEAR | 19.6 |
| XENE Xenon Pharmaceuticals Inc. | $3.4B | -7.6 | -43.6 | -109.7 | — | -100.0 | 3 | BEARISH | -11.7 |
| TSHA Taysha Gene Therapies, Inc. | $1.3B | -10.1 | -47.1 | 961.0 | — | -32.3 | 3 | BEARISH | -10.5 |
| ARVN Arvinas, Inc. | $470M | 39.1 | 1.6 | -519.3 | 67.8 | -15.0 | 4 | BEARISH | -19.1 |
| CAMP CAMP4 Therapeutics Corporation | $210M | -1.6 | -545.9 | 48.4 | -1884.8 | 40.2 | 2 | BEARISH | -1.9 |
| SNBIF SanBio Company Limited | $1.3B | -19.5 | -55.8 | -2935.2 | — | — | 3 | BEARISH | 0.0 |
| OVID Ovid Therapeutics Inc. | $420M | -4.7 | -26.0 | -43.7 | -2047.6 | -76.2 | 3 | BEARISH | 38.6 |
| RZLT Rezolute, Inc. | $370M | -5.4 | -59.0 | 1060.6 | — | — | 2 | BEARISH | -55.3 |
| TNGX Tango Therapeutics, Inc. | $3.9B | -27.3 | -21.3 | -253.2 | — | 121.5 | 3 | BEARISH | 205.2 |
| TRVI Trevi Therapeutics, Inc. | $1.8B | -39.6 | -19.7 | -1451.7 | — | — | 3 | BEARISH | 27.0 |
| QURE uniQure N.V. | $1.6B | -5.9 | -157.6 | 37.9 | -1387.8 | 30.2 | 4 | BEARISH | -60.2 |
| BPMUF Basilea Pharmaceutica AG | $960M | 16.9 | 39.5 | 75.9 | 23.5 | 4.5 | 7 | BEARISH | 27.1 |
| DNA Ginkgo Bioworks Holdings, Inc. | $670M | -2.3 | -56.3 | -44.0 | -231.7 | -51.5 | 2 | BEARISH | -16.9 |
| RAPP Rapport Therapeutics, Inc. Common Stock | $1.2B | -9.1 | -40.0 | 3981.5 | — | — | 4 | BEARISH | 6.2 |
| MEOBF Mesoblast Limited | $2.0B | -29.4 | -9.9 | -14.4 | -23.4 | 613.8 | 5 | BEARISH | -20.0 |
| PRAX Praxis Precision Medicines, Inc. | $7.1B | -20.8 | -38.9 | -51.2 | — | -100.0 | 4 | BEARISH | 53.8 |
| CLDX Celldex Therapeutics, Inc. | $2.3B | -6.9 | -43.9 | -13685.9 | -334104.5 | -98.1 | 1 | BEARISH | 12.8 |
| BCRX BioCryst Pharmaceuticals, Inc. | $1.9B | -5.6 | 87.8 | 62.3 | 35.9 | 68.7 | 5 | BEARISH | 12.5 |
| APMD Apnimed, Inc. | $790M | — | — | — | — | — | — | BEARISH | — |
| STTK Shattuck Labs, Inc. | $550M | -11.4 | -39.2 | -29.3 | — | -66.6 | 4 | BEARISH | 200.5 |
| BNTC Benitec Biopharma Inc. | $300M | -8.9 | -33.2 | 1840.8 | — | — | 3 | BEARISH | -35.5 |
| ELDN Eledon Pharmaceuticals, Inc. | $190M | -2.4 | -110.7 | 411.1 | — | — | 2 | BEARISH | -30.8 |
| PPTDF PeptiDream Inc. | $870M | -38.0 | -7.1 | -9.6 | -25.7 | 47.8 | 4 | BEARISH | -38.7 |
| CSPHF CStone Pharmaceuticals | $1.4B | -14.4 | -51.4 | -340.2 | -123.0 | 135.6 | 5 | BEARISH | -15.4 |
| DRTSW Alpha Tau Medical Ltd. | $1.2B | -13.0 | -141.7 | -17.1 | — | — | 3 | BEARISH | 807.7 |
| HNSBF Hansa Biopharma AB (publ) | $330M | -4.6 | 159.8 | 1182.7 | -541.7 | -3.7 | 2 | BEARISH | -28.2 |
| VOGX Vogenx Inc. | $260M | — | — | — | — | — | — | BEARISH | — |
| PCVX Vaxcyte, Inc. | $9.5B | -8.0 | -36.5 | -66.4 | — | — | 0 | BEARISH | 43.7 |
| IDRSF Idorsia Ltd | $1.4B | -3.5 | 27.1 | -344.5 | -203.1 | -8.1 | 1 | BEARISH | 19.6 |
| VBIZF Viva Biotech Holdings | $400M | 13.1 | 4.5 | 4.2 | 8.0 | 2.9 | 7 | BEARISH | -35.1 |
| RCKT Rocket Pharmaceuticals, Inc. | $250M | -15.5 | -4.8 | -137.8 | — | — | 3 | BEARISH | -36.4 |
| DNLI Denali Therapeutics Inc. | $2.9B | -6.7 | -54.9 | -281.7 | -3539.2 | — | 3 | BEARISH | 20.4 |
| CRVS Corvus Pharmaceuticals, Inc. | $890M | -16.5 | -35.4 | -415.6 | — | — | 4 | BEARISH | 43.4 |
| SVRA Savara Inc. | $870M | -8.4 | -105.5 | -15438.9 | — | — | 2 | BEARISH | 11.5 |
| IMRX Immuneering Corporation | $240M | -3.7 | -52.1 | -112.8 | — | — | 4 | BEARISH | -36.6 |
| ARWR Arrowhead Pharmaceuticals, Inc. | $8.2B | -26.6 | -64.8 | 65.7 | -258.2 | 12.2 | 4 | BEARISH | 55.3 |
| IONS Ionis Pharmaceuticals, Inc. | $7.1B | -12.7 | -105.4 | -58.5 | -42.8 | -7.4 | 3 | BEARISH | -38.0 |
| PTCT PTC Therapeutics, Inc. | $5.1B | -126.1 | 20.6 | -5.4 | 23.2 | -42.8 | 2 | BEARISH | -6.5 |
| AMLX Amylyx Pharmaceuticals, Inc. | $3.4B | -19.9 | -74.7 | 2020.5 | — | 100.0 | 5 | BEARISH | 99.7 |
| MBX MBX Biosciences, Inc. Common Stock | $2.3B | -22.1 | -33.2 | 1634.0 | — | — | 2 | BEARISH | 211.6 |
| VERA Vera Therapeutics, Inc. | $2.0B | -5.1 | -91.8 | 2030.6 | — | — | 1 | BEARISH | 2.6 |
| IMTX Immatics N.V. | $1.1B | -4.1 | -47.8 | -858.3 | -683.4 | -68.0 | 2 | BEARISH | -28.7 |
| KURA Kura Oncology, Inc. | $850M | -2.9 | -167.7 | 56.3 | -327.3 | -7.3 | 1 | BEARISH | 2.1 |
| ATTO Attovia Therapeutics, Inc. | $630M | -15.3 | -294.4 | -1137.2 | -4597.1 | -50.5 | 4 | BEARISH | 272.2 |
| OCS Oculis Holding AG | $490M | -4.7 | -44.0 | -31.0 | — | -6.9 | 3 | BEARISH | -63.1 |
| AURA Aura Biosciences, Inc. | $650M | -3.5 | -53.5 | -1360.0 | — | — | 4 | BEARISH | 7.5 |
| TTRX Turn Therapeutics Inc. | $310M | -36.1 | -952.4 | 115.0 | — | — | 2 | BEARISH | 105.1 |
| ARCT Arcturus Therapeutics Holdings Inc. | $280M | -3.4 | -46.3 | -2501.0 | -803.8 | -79.1 | 1 | BEARISH | 0.1 |
| SPHRY Starpharma Holdings Limited | $220M | -26.0 | -46.5 | -441.4 | -725.1 | 186.8 | 4 | BEARISH | 73.3 |
| DNTH Dianthus Therapeutics, Inc. | $4.3B | -610.5 | -4.1 | -60.1 | -6598.6 | -60.8 | 3 | BEARISH | 141.6 |
| GHRS GH Research PLC | $1.2B | -20.0 | -18.8 | 2015.5 | — | — | 2 | BEARISH | 43.5 |
| ABUS Arbutus Biopharma Corp | $830M | 5.4 | 89.6 | 86.7 | -507.2 | 1078.8 | 4 | BEARISH | -1.6 |
| QTTB Q32 Bio Inc. | $260M | 3.1 | 72.1 | 435.2 | — | — | 5 | BEARISH | 193.3 |
| GNNSF Genscript Biotech Corporation | $9.6B | -14.1 | -15.4 | 2.9 | -32.0 | 53.1 | 4 | BEARISH | 97.7 |
| ANL Adlai Nortye Ltd. | $560M | -5.5 | -22.4 | -317.5 | -36.3 | 223.4 | 4 | BEARISH | 549.1 |
| ARTV Artiva Biotherapeutics, Inc. | $300M | -1.3 | -36.6 | -954.6 | — | — | 3 | BEARISH | -21.1 |
| PLX Protalix BioTherapeutics, Inc. | $210M | 10.5 | 31.2 | 47.1 | 19.0 | 30.1 | 5 | BEARISH | 7.2 |
| CGON CG Oncology Inc. | $5.5B | -23.5 | -26.4 | -2066.1 | -6832.8 | 1030.3 | 3 | BEARISH | 44.1 |
| CRSP CRISPR Therapeutics AG | $4.8B | -10.7 | -26.1 | -253.2 | -895.3 | -62.7 | 3 | BEARISH | -23.9 |
| PBLS Parabilis Medicines, Inc. | $3.0B | — | — | — | — | — | — | BEARISH | — |
| MLYS Mineralys Therapeutics, Inc. | $1.8B | -4.9 | -80.9 | 2274.6 | — | — | 2 | BEARISH | -47.0 |
| GENB Generate Biomedicines, Inc. | $1.6B | -7.9 | -28.2 | -175.0 | -1065.2 | — | 1 | BEARISH | — |
| CMPS COMPASS Pathways plc | $1.6B | -2.1 | -319.1 | 48.8 | — | — | 2 | BEARISH | 88.1 |
| NKTR Nektar Therapeutics | $1.1B | -5.7 | -35.8 | -29.2 | -401.0 | -27.2 | 3 | BEARISH | -36.8 |
| AVBP ArriVent BioPharma, Inc. | $1.0B | -4.1 | -53.1 | 2345.1 | — | — | 3 | BEARISH | -17.2 |
| ALMS Alumis Inc. | $880M | -1.8 | -93.6 | 2645.2 | -8557.2 | -63.1 | 2 | BEARISH | 47.2 |
| SANA Sana Biotechnology, Inc. | $700M | -3.2 | -152.9 | -242.3 | — | — | 3 | BEARISH | -55.8 |
| FULC Fulcrum Therapeutics, Inc. | $280M | -3.1 | -32.4 | 2389.1 | — | — | 4 | BEARISH | -59.9 |
| IPSC Century Therapeutics, Inc. | $260M | -1.4 | -49.7 | -60.0 | — | -100.0 | 2 | BEARISH | 151.2 |
| CAMRF Camurus AB | $3.7B | 58.2 | 15.8 | 89.3 | 34.3 | -0.2 | 6 | BEARISH | -10.3 |
| ORIC ORIC Pharmaceuticals, Inc. | $1.4B | -6.7 | -39.8 | -102.9 | — | — | 3 | BEARISH | -31.3 |
| IMVT Immunovant, Inc. | $5.9B | -10.2 | -80.1 | 707.5 | -2159.6 | — | 2 | BEARISH | 52.5 |
| HRMY Harmony Biosciences Holdings, Inc. | $2.1B | 12.0 | 20.5 | 35.7 | 28.9 | 24.3 | 5 | BEARISH | 25.4 |
| ANRO Alto Neuroscience, Inc. | $860M | -9.3 | -49.2 | -201.4 | — | — | 3 | BEARISH | 110.7 |
| DSGN Design Therapeutics, Inc. | $640M | -9.1 | -34.1 | 1787.8 | — | — | 1 | BEARISH | 85.5 |
| RCUS Arcus Biosciences, Inc. | $2.3B | -4.6 | -89.2 | 309.6 | -222.0 | -55.3 | 0 | BEARISH | 4.8 |
| AUTL Autolus Therapeutics plc | $410M | -1.5 | -132.9 | 451.5 | -85.6 | 292.0 | 3 | BEARISH | 1.3 |
| AVLN Avalyn Pharma Inc. Common Stock | $1.1B | — | — | — | — | — | — | BEARISH | — |
| BCAX Bicara Therapeutics Inc. Common Stock | $1.1B | -5.6 | -41.0 | 583.9 | — | — | 2 | BEARISH | 2.0 |
| MNKD MannKind Corporation | $1.0B | -23.4 | 71.4 | 4.0 | -17.4 | 30.5 | 2 | BEARISH | -38.0 |
| GLUE Monte Rosa Therapeutics, Inc. | $920M | -4.8 | -42.7 | 149.9 | -483.9 | -83.9 | 3 | BEARISH | -4.3 |
| WVE Wave Life Sciences Ltd. | $630M | -3.2 | -80.0 | -1243.7 | -470.5 | -35.1 | 4 | BEARISH | -51.6 |
| LRMR Larimar Therapeutics, Inc. | $240M | -1.2 | -139.6 | 590.9 | — | — | 2 | BEARISH | -43.2 |
| KRYS Krystal Biotech, Inc. | $9.2B | 38.6 | 20.1 | 40.4 | 45.9 | 22.6 | 7 | BEARISH | 72.2 |
| INVA Innoviva, Inc. | $1.5B | 4.3 | 36.7 | 15.0 | -69.8 | 19.8 | 7 | BEARISH | 18.2 |
| ACHV Achieve Life Sciences, Inc. | $670M | -4.4 | -845.0 | 24.6 | — | — | 2 | BEARISH | 38.6 |
| TECX Tectonic Therapeutic, Inc. | $390M | -4.5 | -33.8 | -6371.3 | — | — | 1 | BEARISH | 18.6 |
| EIKN Eikon Therapeutics, Inc. Common Stock | $390M | — | — | — | — | — | — | BEARISH | — |
| CLVLF Clinuvel Pharmaceuticals Limited | $250M | 10.6 | 13.2 | 126.7 | 41.1 | -1.1 | 6 | BEARISH | -32.0 |
| RNAC Cartesian Therapeutics, Inc. | $190M | -1.1 | 241.0 | 37.3 | — | 44.0 | 2 | BEARISH | -29.5 |
| NAGE Niagen Bioscience Inc | $190M | 12.9 | 21.8 | 44.7 | 3.2 | 11.0 | 6 | BEARISH | -67.0 |
| IBRX ImmunityBio, Inc. | $8.7B | -8.8 | 122.7 | 33.7 | -449.6 | 192.9 | 4 | BEARISH | 249.4 |
| DRTS Alpha Tau Medical Ltd | $1.2B | -13.0 | -141.7 | -17.1 | — | — | 3 | BEARISH | 219.4 |
| SLDB Solid Biosciences Inc. | $630M | -3.2 | -65.5 | -1012.6 | — | — | 3 | BEARISH | 10.1 |
| NWPHF Newron Pharmaceuticals S.p.A. | $410M | -6.7 | 83.9 | -32.1 | -513.4 | — | 1 | BEARISH | — |
| OLMA Olema Pharmaceuticals, Inc. | $560M | -3.3 | -52.7 | 585.3 | — | — | 2 | BEARISH | -12.3 |
| CBIO Crescent Biopharma, Inc. | $480M | -1.8 | -107.7 | 1928.6 | — | — | 5 | BEARISH | 4.6 |
| BLSM BlossomHill Therapeutics, Inc. | $430M | — | — | — | — | — | — | BEARISH | — |
| TARS Tarsus Pharmaceuticals, Inc. | $3.2B | -65.1 | -13.7 | 268.1 | -10.7 | 105.2 | 5 | BEARISH | 7.1 |
| AAPG Ascentage Pharma Group International | $1.4B | -6.1 | -236.8 | -144.8 | -270.2 | 170.9 | 3 | BEARISH | -58.7 |
| OMER Omeros Corporation | $1.2B | 9.1 | -89.2 | 71.8 | 46.4 | — | 5 | BEARISH | 131.7 |
| ASCLF Ascletis Pharma Inc. | $770M | -7.8 | -28.4 | -7144.0 | — | -60.6 | 2 | BEARISH | -40.0 |
| NVCT Nuvectis Pharma, Inc. | $650M | -14.0 | -214.6 | 174.4 | — | — | 1 | BEARISH | 197.4 |
| FDMT 4D Molecular Therapeutics, Inc. | $600M | -4.3 | -43.3 | -182.0 | -1929.0 | 278712.1 | 4 | BEARISH | 5.5 |
| PHAT Phathom Pharmaceuticals, Inc. | $460M | -4.7 | 26.4 | 8.9 | -23.7 | 110.2 | 4 | BEARISH | -55.7 |
| EPRX Eupraxia Pharmaceuticals Inc. | $450M | -6.9 | -68.6 | 8742.2 | — | — | 3 | BEARISH | 29.4 |
| AGEN Agenus Inc. | $290M | 2.4 | -33.2 | -20.4 | -1.6 | 30.5 | 6 | BEARISH | 60.6 |
| GALT Galectin Therapeutics Inc. | $210M | -8.0 | 21.9 | 99.4 | — | — | 2 | BEARISH | -35.4 |
| BLTE Belite Bio, Inc | $5.9B | -52.9 | -20.8 | -11.5 | — | — | 3 | BEARISH | 57.0 |
| NUVB Nuvation Bio Inc. | $1.6B | -10.3 | -47.8 | 70.2 | -198.3 | 1083.6 | 4 | BEARISH | -6.2 |
| NVAX Novavax, Inc. | $1.6B | -6.6 | 323.7 | 29.2 | -94.2 | -61.6 | 2 | BEARISH | 17.6 |
| MGTX MeiraGTx Holdings plc | $880M | 12.3 | 72.3 | 96.7 | 50.0 | 948.3 | 7 | BEARISH | 7.8 |
| LXRX Lexicon Pharmaceuticals, Inc. | $630M | -9.8 | -40.2 | -99.7 | -4591.8 | -29.0 | 3 | BEARISH | 24.4 |
| CLYM Climb Bio, Inc. | $590M | -11.6 | -27.1 | -88.6 | — | — | 2 | BEARISH | 380.9 |
| MNPR Monopar Therapeutics Inc. | $470M | -30.7 | -19.5 | 523.8 | — | — | 2 | BEARISH | -11.9 |
| AVIR Atea Pharmaceuticals, Inc. | $320M | -2.0 | -58.1 | 974.6 | — | — | 3 | BEARISH | 29.9 |
| CYTK Cytokinetics, Incorporated | $8.5B | -8.5 | 329.8 | 811.2 | -622.8 | -17.2 | 2 | BEARISH | 6.4 |
| NAMS NewAmsterdam Pharma Company N.V. | $2.3B | -9.4 | -36.8 | 8216.2 | -1732.9 | -88.9 | 2 | BEARISH | -42.6 |
| HBMHF HBM Holdings Limited | $1.3B | 12.5 | 24.1 | 53.0 | 53.0 | 54.6 | 4 | BEARISH | -38.1 |
| GERN Geron Corporation | $720M | -11.5 | -29.2 | -74.1 | -29.0 | 24.4 | 2 | BEARISH | -7.3 |
| SLBT SL Science Holding Ltd | $640M | — | — | — | — | — | — | BEARISH | — |
| GYRE Gyre Therapeutics, Inc. | $620M | -32.8 | -15.6 | -22.3 | -36.4 | 16.8 | 3 | BEARISH | -20.1 |
| ANNX Annexon, Inc. | $610M | -3.2 | -105.3 | -11323.3 | — | — | 2 | BEARISH | 17.1 |
| AGMB AgomAb Therapeutics N.V. American Depositary Shares | $450M | — | — | — | — | — | — | BEARISH | — |
| ASMB Assembly Biosciences, Inc. | $400M | 37.0 | -0.0 | 56.2 | -28.8 | 125.1 | 4 | BEARISH | -30.6 |
| RLMD Relmada Therapeutics, Inc. | $350M | -3.5 | -55.7 | 460.5 | — | — | 3 | BEARISH | 52.9 |
| MPLT MapLight Therapeutics, Inc. | $340M | -1.6 | -57.5 | -366.6 | — | — | 2 | BEARISH | — |
| CTNM Contineum Therapeutics, Inc. | $270M | -5.2 | -28.0 | -541.6 | — | — | 4 | BEARISH | -18.6 |
| LXEO Lexeo Therapeutics, Inc. Common Stock | $230M | -2.5 | -46.8 | -249.1 | — | — | 3 | BEARISH | -68.9 |
| BOVNF BioInvent International AB (publ) | $220M | -2.8 | -88.2 | 20101.5 | -964.0 | -87.2 | 1 | BEARISH | 0.0 |
| BBOT BridgeBio Oncology Therapeutics Inc. | $210M | -0.0 | -56.4 | -157.3 | — | — | 1 | BEARISH | -75.5 |
| IDYA IDEAYA Biosciences, Inc. | $3.4B | -17.4 | -16.2 | -42.9 | -1269.6 | 3244.7 | 4 | BEARISH | 14.8 |
| TLX Telix Pharmaceuticals Limited | $3.1B | 92.5 | 8.6 | -1.0 | 8.0 | 10.5 | 4 | BEARISH | -16.5 |
| PGEN Precigen, Inc. | $2.2B | -5.4 | -4640.4 | -30.1 | 36.5 | 1875.0 | 5 | BEARISH | 42.0 |
| ZVRA Zevra Therapeutics, Inc. | $580M | 10.5 | 34.8 | -1356.4 | 22.1 | 119.4 | 6 | BEARISH | -5.2 |
| IRD Opus Genetics, Inc. | $290M | -2.7 | -4796.5 | 59.8 | -1072.6 | -36.1 | 3 | BEARISH | 73.9 |
| TVTX Travere Therapeutics, Inc. | $4.7B | -112.6 | -151.8 | -21.0 | -20.5 | 77.1 | 6 | BEARISH | 81.3 |
| URGN UroGen Pharma Ltd. | $1.7B | -17.2 | 86.5 | 119.0 | -19.8 | 169.5 | 2 | BEARISH | 78.8 |
| MDCLF MedinCell S.A. | $1.1B | -29.2 | 472.2 | 81.6 | -152.1 | -14.8 | 3 | BEARISH | 333.5 |
| IMMX Immix Biopharma, Inc. | $680M | -9.3 | -34.2 | 1509.2 | — | — | 4 | BEARISH | 123.0 |
| CADL Candel Therapeutics, Inc. | $610M | -5.9 | -81.8 | 219.4 | — | — | 2 | BEARISH | 52.8 |
| GNFTF Genfit S.A. | $470M | -5.2 | -5084.0 | -322.7 | -124.0 | 27.5 | 3 | BEARISH | 153.5 |
| IKT Inhibikase Therapeutics, Inc. | $220M | -3.3 | -52.0 | 920.5 | — | — | 3 | BEARISH | 1.9 |
| REGMF RemeGen Co., Ltd. | $5.6B | 9.1 | 108.3 | 139.6 | 83.4 | 283.6 | 7 | BEARISH | -7.7 |
| GENSF Genus plc | $1.8B | 5.4 | 45.4 | 9.0 | 80.4 | -3.8 | 5 | BEARISH | -19.4 |
| OCUL Ocular Therapeutix, Inc. | $1.4B | -4.7 | -73.0 | -31671.3 | -584.5 | -8.1 | 3 | BEARISH | -41.5 |
| GPCR Structure Therapeutics Inc. | $1.2B | -7.1 | -20.2 | -1134.3 | — | — | 3 | BEARISH | -18.3 |
| SNDX Syndax Pharmaceuticals, Inc. | $1.2B | -5.4 | -255.9 | -270.9 | -67.8 | 222.3 | 4 | BEARISH | 1.2 |
| AKTS Aktis Oncology, Inc. | $850M | -15.8 | -29.9 | 276.4 | -713.5 | -36.1 | 5 | BEARISH | 373763.6 |
| ARDX Ardelyx, Inc. | $770M | -13.2 | -38.6 | -22.7 | -13.8 | 16.8 | 4 | BEARISH | -40.5 |
| CTMX CytomX Therapeutics, Inc. | $510M | -5.2 | -37.8 | 305.9 | -1457.4 | -87.0 | 2 | BEARISH | -29.1 |
| PROK ProKidney Corp. | $470M | -2.7 | 9.2 | 13.2 | -18948.0 | 55.2 | 1 | BEARISH | -52.5 |
| FTH Faeth Therapeutics, Inc. | $440M | — | — | — | — | — | — | BEARISH | — |
| ALLO Allogene Therapeutics, Inc. | $430M | -1.9 | -42.4 | -81.9 | -919.8 | — | 5 | BEARISH | 2.5 |
| AVCTF Avacta Group Plc | $420M | -6.7 | -2083.2 | -753.6 | -33970.3 | -99.7 | 5 | BEARISH | -18.7 |
| SPRY ARS Pharmaceuticals, Inc. | $400M | -1.7 | -210.3 | -424.3 | -185.2 | 4.1 | 2 | BEARISH | -59.1 |
| CAPR Capricor Therapeutics, Inc. | $340M | -2.5 | -73.7 | -107.5 | — | -100.0 | 3 | BEARISH | -1.6 |
| KYTX Kyverna Therapeutics, Inc. | $330M | -1.9 | -87.2 | 14267.8 | — | — | 2 | BEARISH | -24.3 |
| SPHDF Santhera Pharmaceuticals Holding AG | $280M | -6.6 | 729.6 | 111.3 | -44.5 | 106.3 | 7 | BEARISH | 49.1 |
| ORYZF Oryzon Genomics S.A. | $250M | -80.4 | -3.0 | -7.2 | -1.6 | 12.6 | 4 | BEARISH | -14.1 |
| OCGN Ocugen, Inc. | $250M | -2.9 | 1211.7 | 190.2 | -1671.8 | -3.7 | 2 | BEARISH | -52.4 |
| ABEO Abeona Therapeutics Inc. | $250M | -3.9 | -43.1 | -5983.3 | -177.4 | 6280.0 | 2 | BEARISH | -18.8 |
| VNDA Vanda Pharmaceuticals Inc. | $240M | -0.9 | -77.8 | -201.0 | -123.7 | 6.0 | 3 | BEARISH | -27.4 |
| HLOSF Healios K.K. | $240M | 56.3 | 3.7 | -129.2 | 17028.6 | -47.1 | 4 | BEARISH | -48.6 |
| IPHYF Innate Pharma S.A. | $210M | -2.5 | 267.9 | 119.2 | -343.8 | 32.0 | 3 | BEARISH | -24.5 |
| EVMN Evommune, Inc. | $190M | -1.5 | -29.6 | -82.4 | — | — | 2 | BEARISH | — |
| BIOA BioAge Labs Inc. | $190M | -2.3 | -28.2 | -142.3 | -1064.7 | 168.1 | 4 | BEARISH | -28.0 |
| AXSM Axsome Therapeutics, Inc. | $7.6B | -37.9 | -245.1 | 859.1 | -23.5 | 56.9 | 5 | BEARISH | 9.8 |
| TRSBF 3SBio Inc. | $4.3B | 3.4 | 37.1 | 80.3 | 25.3 | 93.8 | 7 | BEARISH | -51.7 |
| VKTX Viking Therapeutics, Inc. | $3.1B | -5.3 | -88.9 | 495.6 | — | — | 1 | BEARISH | -27.7 |
| BRCTF BioArctic AB | $2.6B | 263.7 | 5.2 | 77.4 | -4.5 | -46.1 | 3 | BEARISH | -8.6 |
| ZLDPF Zealand Pharma A/S | $2.4B | 5.8 | 16.3 | 57.2 | 87.2 | -49.2 | 3 | BEARISH | -54.1 |
| INCPF InnoCare Pharma Limited | $2.4B | 18.7 | 12.6 | 45.8 | 23.1 | 108.5 | 4 | BEARISH | -50.9 |
| IVEVF Inventiva S.A. | $750M | -6.2 | -988.4 | -371.6 | -347346.6 | -99.7 | 3 | BEARISH | -22.8 |
| RGNX REGENXBIO Inc. | $440M | -1.7 | -137.6 | -368.4 | 21.0 | 12.0 | 2 | BEARISH | -49.4 |
| ALT Altimmune, Inc. | $410M | -2.6 | -28.9 | -43.1 | — | 55.0 | 4 | BEARISH | -46.0 |
| AVTX Avalo Therapeutics, Inc. | $370M | -1.4 | -36.3 | -148.4 | — | -86.6 | 4 | BEARISH | -61.6 |
| DMTRF 3-D Matrix, Ltd. | $310M | 11.9 | 75.0 | 31.1 | 9.4 | 57.0 | 6 | BEARISH | 61.3 |
| CABA Cabaletta Bio, Inc. | $250M | -0.9 | -93.2 | -1308.0 | — | — | 3 | BEARISH | -40.9 |
| SCTX Scribe Therapeutics Inc. | $250M | — | — | — | — | — | — | BEARISH | — |
| ACIU AC Immune S.A. | $250M | -4.2 | -78.5 | 96.7 | 12.4 | -39.5 | 2 | BEARISH | -30.8 |
| PALI Palisade Bio, Inc. | $230M | -2.3 | -51.4 | 815.6 | -2114.8 | — | 5 | BEARISH | -31.0 |
| MDXG MiMedx Group, Inc. | $570M | 96.6 | 2.9 | 5.8 | -23.1 | -2.4 | 6 | BEARISH | -42.3 |
| MYGN Myriad Genetics, Inc. | $560M | -5.3 | -32.5 | -19.5 | -22.7 | -3.2 | 4 | BULLISH | -22.8 |
| EVH Evolent Health, Inc. | $540M | -1.0 | -79.0 | -1.8 | -4.3 | -4.5 | 5 | BULLISH | -43.4 |
| IOBCF Ion Beam Applications S.A. | $550M | 19.7 | 20.6 | 14.0 | 2.9 | 7.0 | 5 | BULLISH | 39.5 |
| TCMD Tactile Systems Technology, Inc. | $540M | 21.4 | 11.9 | 13.8 | 9.1 | 17.2 | 8 | BULLISH | 55.4 |
| SOPH SOPHiA GENETICS S.A. | $630M | -6.7 | -101.2 | -155.2 | -95.9 | 23.6 | 3 | LEAN BULL | 77.4 |
| GMRS GMR Solutions Inc. | $580M | — | — | — | — | — | — | LEAN BULL | — |
| FLGT Fulgent Genetics, Inc. | $550M | -7.3 | -8.0 | -12.6 | -34.6 | 6.8 | 4 | NEUTRAL | -12.8 |
| RSLBF RaySearch Laboratories AB (publ) | $510M | 31.8 | 26.1 | 21.8 | 7.2 | 1.2 | 6 | LEAN BEAR | -35.8 |
| ANGO AngioDynamics, Inc. | $520M | -15.4 | -19.2 | -20.5 | -8.8 | 8.2 | 5 | LEAN BEAR | -0.7 |
| BJTRF Beijing Tong Ren Tang Chinese Medicine Company Limited | $540M | 10.3 | 20.8 | 23.4 | 32.9 | 697.9 | 9 | LEAN BEAR | 0.0 |
| PKBFF PeakBirch Commerce Inc. | $540M | -0.0 | -16609.0 | 16544.6 | -58.8 | -69.1 | 3 | BEARISH | 0.0 |
| BOIRF Boiron S.A. | $550M | 12.7 | 7.2 | 7.8 | 2.0 | 97.0 | 5 | BEARISH | 10.5 |
| ZRSEF DocMorris AG | $520M | -10.1 | -30.1 | -29.3 | -8.9 | 11.0 | 2 | BEARISH | 0.0 |
| DCTH Delcath Systems, Inc. | $500M | 1344.2 | 0.5 | -2.7 | 9.2 | 35.8 | 6 | BEARISH | 44.2 |
| IRWD Ironwood Pharmaceuticals, Inc. | $570M | 4.4 | -55.3 | 93.9 | 45.4 | 26.2 | 7 | BEARISH | 111.5 |
| HELP Helus Pharma Inc. | $630M | -2.6 | -56.3 | -143.0 | — | — | 2 | BEARISH | — |
| AVR Anteris Technologies Global Corp. | $570M | -2.2 | -75.1 | 3136.2 | -2884.3 | 31.1 | 5 | BEARISH | 20.0 |
| EVOTF Evotec SE | $590M | -2.6 | -26.1 | -14.9 | -32.5 | -7.7 | 2 | BEARISH | -54.3 |
| CRWRF Craneware plc | $620M | 25.9 | 6.0 | 6.8 | 9.7 | 4.2 | 7 | BEARISH | -43.9 |
| NNCSF Nanosonics Limited | $620M | 53.0 | 8.3 | 15.6 | 8.1 | 2.4 | 4 | BEARISH | -39.9 |
| MDXG MiMedx Group, Inc. | $570M | 96.6 | 2.9 | 5.8 | -23.1 | -2.4 | 6 | BEARISH | -42.3 |
| CAI Caris Life Sciences, Inc. | $9.1B | 91.5 | 20.1 | 61.1 | -0.2 | 445.5 | 7 | BULLISH | 8.4 |
| HNGE Hinge Health, Inc. | $9.0B | 84.6 | 30.4 | -235.0 | 20.5 | 417.7 | 7 | BULLISH | 129.6 |
| RGEDF Chemical Works of Gedeon Richter Plc | $7.4B | 10.7 | 16.2 | 24.3 | 15.9 | 1.8 | 5 | BULLISH | 32.8 |
| ALKS Alkermes plc | $7.3B | 110.1 | 3.9 | 2.9 | 0.1 | 10.8 | 4 | BULLISH | 48.7 |
| AMRX Amneal Pharmaceuticals, Inc. | $6.5B | 43.0 | -395.8 | 16.0 | 7.2 | 9.3 | 8 | BULLISH | 103.2 |
| BLCO Bausch + Lomb Corporation | $6.2B | -36.9 | -2.7 | 2.8 | -1.0 | 8.8 | 5 | BULLISH | 13.5 |
| KNSA Kiniksa Pharmaceuticals International, plc | $6.0B | 63.0 | 14.0 | 51.6 | 10.4 | 58.9 | 7 | BULLISH | 129.1 |
| MANE Veradermics, Incorporated | $5.8B | — | — | — | — | — | — | BULLISH | — |
| TFX Teleflex Incorporated | $5.8B | -5.9 | -28.8 | 1.3 | 17.9 | -14.5 | 5 | BULLISH | 5.8 |
| LFST LifeStance Health Group, Inc. | $4.9B | 101.0 | 3.4 | 4.1 | 5.4 | 20.4 | 7 | BULLISH | 151.9 |
| VCYT Veracyte, Inc. | $3.9B | 35.8 | 8.8 | 10.7 | 17.0 | 17.3 | 8 | BULLISH | 36.9 |
| ATRC AtriCure, Inc. | $3.0B | 289.6 | 2.2 | 2.9 | 5.8 | 13.9 | 8 | BULLISH | 63.9 |
| BVNRY Bavarian Nordic A/S | $2.9B | 13.0 | 12.3 | 7.1 | 36.0 | -5.8 | 7 | BULLISH | 1.9 |
| NRIX Nurix Therapeutics, Inc. | $2.8B | 10.6 | 44.0 | -1896.6 | 81.7 | 738.8 | 8 | BULLISH | 140.8 |
| GNNDY GN Store Nord A/S | $2.4B | -29.9 | -5.4 | 1.6 | -1.0 | -25.4 | 4 | BULLISH | -5.1 |
| FTRE Fortrea Holdings Inc. | $2.2B | -26.2 | -15.3 | 0.6 | -1.9 | -2.1 | 6 | BULLISH | 116.2 |
| AGIO Agios Pharmaceuticals, Inc. | $2.2B | -5.4 | -34.3 | -82.5 | -225.1 | 140.6 | 4 | BULLISH | -12.2 |
| LKFT Lakefront Biotherapeutics N.V. | $2.1B | — | — | — | — | — | — | BULLISH | — |
| SGRY Surgery Partners, Inc. | $2.1B | -33.7 | -5.2 | 5.9 | -1.8 | 4.0 | 5 | BULLISH | 2.4 |
| SEPN Septerna Inc | $1.9B | -81.5 | -6.3 | -93.1 | -48.7 | 17878.5 | 5 | BULLISH | 103.7 |
| COAG Hemab Therapeutics Holdings, Inc. Common Stock | $1.6B | — | — | — | — | — | — | BULLISH | — |
| CERT Certara, Inc. | $1.6B | -24.5 | -6.7 | 0.6 | -59.3 | 0.7 | 6 | BULLISH | -13.5 |
| MRCHF H.U. Group Holdings, Inc. | $1.3B | 22.0 | 7.2 | 3.3 | 2.5 | 1.8 | 9 | BULLISH | -7.4 |
| LTGHY Life Healthcare Group Holdings Limited | $1.1B | 2.7 | 68.5 | 10.7 | 6.2 | -3.0 | 4 | BULLISH | 14.5 |
| VSTM Verastem, Inc. | $910M | -4.1 | -471.2 | 6197.3 | -86.5 | 3995.7 | 4 | BULLISH | 27.0 |
| SOLTF Nxera Pharma Co., Ltd. | $770M | -15.8 | -12.0 | -1.7 | -2.6 | 7.5 | 4 | BULLISH | 38.2 |
| CTKB Cytek Biosciences, Inc. | $730M | -9.6 | -23.0 | -40.8 | -25.3 | 5.4 | 3 | BULLISH | 40.4 |
| RCEL Avita Medical Inc. | $390M | -11.0 | 211.5 | -292.6 | -35.3 | 1.0 | 4 | BULLISH | 305.0 |
| HQY HealthEquity, Inc. | $8.6B | 36.3 | 11.4 | 9.9 | 18.7 | 7.3 | 8 | BULLISH | 4.5 |
| PACS PACS Group, Inc. | $7.5B | 28.0 | 28.1 | 6.9 | 5.3 | 15.2 | 8 | BULLISH | 277.8 |
| SSMXY Sysmex Corporation | $7.4B | 30.7 | 8.5 | 10.0 | 6.7 | 6.2 | 5 | BULLISH | 4.5 |
| DOCS Doximity, Inc. | $6.0B | 37.2 | 17.2 | 60.2 | 15.5 | 11.2 | 6 | BULLISH | -50.3 |
| MMSI Merit Medical Systems, Inc. | $5.6B | 38.2 | 9.2 | 7.3 | 9.3 | 10.2 | 9 | BULLISH | 13.0 |
| WAY Waystar Holding Corp. | $5.5B | 38.9 | 3.8 | 3.8 | 12.8 | 19.2 | 7 | BULLISH | -28.1 |
| CON Concentra Group Holdings Parent, Inc. | $5.0B | 25.7 | 48.5 | 66.4 | 10.8 | 14.0 | 9 | BULLISH | 92.0 |
| ARQT Arcutis Biotherapeutics, Inc. | $3.9B | 143.7 | 15.9 | 34.7 | 11.6 | 76.1 | 7 | BULLISH | 57.5 |
| MD Pediatrix Medical Group, Inc. | $2.4B | 13.7 | 20.4 | 15.9 | 8.2 | 0.5 | 7 | BULLISH | 64.0 |
| PRGO Perrigo Company plc | $2.2B | -1.3 | -49.6 | 3.1 | 7.3 | -4.2 | 4 | BULLISH | -23.7 |
| VCEL Vericel Corporation | $2.2B | 90.6 | 7.2 | 5.9 | 2.8 | 23.0 | 7 | BULLISH | 19.1 |
| BOEUF Bonesupport Holding AB (publ) | $2.1B | 78.2 | 29.2 | 54.1 | 22.6 | 23.4 | 8 | BULLISH | 28.9 |
| MRVI Maravai LifeSciences Holdings, Inc. | $2.1B | -15.3 | -32.9 | 24.4 | -24.1 | -3.3 | 5 | BULLISH | 142.2 |
| AMN AMN Healthcare Services, Inc. | $1.9B | 17.2 | 15.6 | 8.9 | 3.1 | 24.0 | 8 | BULLISH | 120.8 |
| HCSG Healthcare Services Group, Inc. | $1.7B | 16.0 | 20.4 | 27.0 | 5.2 | 4.0 | 7 | BULLISH | 31.8 |
| ARDT Ardent Health Inc. | $1.7B | 21.6 | 6.0 | 13.5 | 1.0 | 3.3 | 5 | BULLISH | -22.3 |
| KLRA Kailera Therapeutics, Inc. | $1.7B | — | — | — | — | — | — | BULLISH | — |
| GDRX GoodRx Holdings, Inc. | $1.2B | 65.6 | 2.5 | 3.5 | 4.3 | -1.8 | 6 | BULLISH | -11.9 |
| SPTX Seaport Therapeutics, Inc. Common Stock | $1.1B | — | — | — | — | — | — | BULLISH | — |
| HSTM HealthStream, Inc. | $1.1B | 47.8 | 6.0 | 6.5 | 8.0 | 8.8 | 8 | BULLISH | 30.1 |
| CBLL CeriBell, Inc. | $1.0B | -15.5 | -43.9 | -263.7 | -68.6 | 69.3 | 3 | BULLISH | 111.2 |
| BVS Bioventus Inc. | $1.0B | 18.1 | 28.0 | 21.3 | 21.8 | 3.1 | 7 | BULLISH | 107.8 |
| SIBN SI-BONE, Inc. | $960M | -63.3 | -8.3 | -32.2 | -7.3 | 15.3 | 6 | BULLISH | 38.4 |
| SGP SpyGlass Pharma, Inc. Common Stock | $950M | — | — | — | — | — | — | BULLISH | — |
| PHR Phreesia, Inc. | $790M | 71.5 | 3.1 | 16.7 | 1.5 | 12.9 | 4 | BULLISH | -47.7 |
| AONC American Oncology Network, Inc. | $640M | -29.7 | 5.6 | -14.7 | 0.3 | 37.5 | 6 | BULLISH | 132.2 |
| ENTX Entera Bio Ltd. | $510M | -8.8 | -138.9 | 314.4 | — | -100.0 | 1 | BULLISH | 37.8 |
| MOBI Mobia Medical, Inc. Common Stock | $350M | — | — | — | — | — | — | BULLISH | — |
| VRDN Viridian Therapeutics, Inc. | $2.5B | -6.7 | -65.7 | 418.2 | -44760.2 | 23220.3 | 4 | BULLISH | 8.7 |
| ADMA ADMA Biologics, Inc. | $2.4B | 15.4 | 41.9 | 35.5 | 30.4 | 8.0 | 5 | BULLISH | -26.4 |
| LWSCF Sienna Senior Living Inc. | $1.6B | 38.9 | 6.7 | 3.9 | 4.4 | 16.2 | 7 | BULLISH | 7.9 |
| AHG Akso Health Group | $1.1B | -20.2 | -50.1 | -44.9 | -546.5 | 22.7 | 4 | BULLISH | -17.1 |
| PRME Prime Medicine, Inc. | $670M | -4.0 | -373.3 | -271.3 | -3649.0 | -17.9 | 3 | BULLISH | -18.4 |
| MYGN Myriad Genetics, Inc. | $560M | -5.3 | -32.5 | -19.5 | -22.7 | -3.2 | 4 | BULLISH | -22.8 |
| XFOR X4 Pharmaceuticals, Inc. | $320M | -2.7 | -113.1 | -281.1 | -183.5 | -51.6 | 4 | BULLISH | -14.5 |
| BIO Bio-Rad Laboratories, Inc. | $9.9B | 45.6 | 3.1 | 2.2 | 57.1 | 1.4 | 7 | BULLISH | 12.1 |
| KYMR Kymera Therapeutics, Inc. | $9.1B | -36.7 | -24.2 | -30.7 | -94.2 | 134.8 | 6 | BULLISH | 100.8 |
| BLLN BillionToOne, Inc. | $5.1B | 166.9 | 6.0 | 25.2 | 7.4 | — | 4 | BULLISH | — |
| IRTC iRhythm Technologies, Inc. | $4.0B | -287.0 | -9.6 | -3.4 | -0.2 | 25.6 | 6 | BULLISH | -31.5 |
| LEGN Legend Biotech Corporation | $3.6B | -42.9 | -8.1 | -8.2 | 8.6 | 59.5 | 4 | BULLISH | -32.3 |
| TNDM Tandem Diabetes Care, Inc. | $1.2B | -20.6 | -48.0 | -8.2 | -8.3 | -7.1 | 4 | BULLISH | 28.6 |
| TDOC Teladoc Health, Inc. | $1.1B | -6.4 | -13.0 | -8.7 | -6.4 | -2.1 | 5 | BULLISH | -31.8 |
| STAA STAAR Surgical Company | $1.1B | 301.5 | 1.1 | 3.5 | 8.6 | 51.3 | 5 | BULLISH | -8.0 |
| LMRI Lumexa Imaging Holdings, Inc. Common Stock | $1.1B | -31.0 | -3.9 | 0.1 | 1.0 | — | 3 | BULLISH | — |
| INDP Indaptus Therapeutics, Inc. | $360M | -0.5 | -318.0 | 6437.4 | — | — | 4 | BULLISH | -8.8 |
| HAE Haemonetics Corporation | $5.4B | 58.5 | 11.2 | 10.1 | 9.7 | 0.4 | 8 | BULLISH | 134.1 |
| HKMPY Hikma Pharmaceuticals PLC | $4.6B | 12.7 | 15.3 | 12.1 | 12.9 | 6.1 | 7 | BULLISH | -5.2 |
| PGNY Progyny, Inc. | $2.2B | 28.5 | 16.2 | 30.2 | 8.0 | 5.5 | 7 | BULLISH | 42.2 |
| VIR Vir Biotechnology, Inc. | $1.8B | -6.2 | -26.1 | -38.8 | 33.5 | 1495.9 | 5 | BULLISH | 93.5 |
| KIDS OrthoPediatrics Corp. | $640M | -14.3 | -11.4 | -4.6 | -10.2 | 14.5 | 6 | BULLISH | 39.9 |
| MASS 908 Devices Inc. | $470M | -13.3 | -25.1 | -103.8 | -74.0 | 4.6 | 5 | BULLISH | 45.2 |
| AVHHL AVITA Medical, Inc. | $360M | -11.0 | 211.5 | -292.6 | -35.3 | 1.0 | 4 | BULLISH | 149.1 |
| MAZE Maze Therapeutics, Inc. | $1.7B | -11.4 | -37.3 | -112.3 | — | — | 3 | BULLISH | 4.3 |
| AZTA Azenta, Inc. | $1.6B | -14.3 | -7.7 | -1.4 | 1.5 | 1.5 | 4 | BULLISH | 21.1 |
| GRRMF Gerresheimer AG | $1.2B | -2.8 | 1.6 | 2.2 | -2.3 | 11.8 | 4 | BULLISH | -27.1 |
| ENOV Enovis Corporation | $1.2B | -1.1 | -54.3 | -13.5 | -0.2 | 4.9 | 4 | BULLISH | -34.4 |
| TDVXF Dynavox Group AB (publ) | $900M | 27.8 | 39.7 | 17.2 | 12.8 | 8.8 | 8 | BULLISH | -22.7 |
| SYRE Spyre Therapeutics, Inc. | $8.3B | -50.4 | -23.0 | 359.8 | — | — | 3 | BULLISH | 323.8 |
| TGTX TG Therapeutics, Inc. | $8.3B | 18.5 | 100.3 | 73.5 | 3.2 | 76.1 | 6 | BULLISH | 69.3 |
| GNGBY Getinge AB (publ) | $7.3B | 25.9 | 9.1 | 8.1 | 8.5 | -3.9 | 7 | BULLISH | 13.6 |
| ORKA Oruka Therapeutics, Inc. | $5.3B | -38.6 | -18.2 | -50.3 | — | — | 4 | BULLISH | 251.6 |
| HTFL Heartflow, Inc. Common Stock | $4.9B | -41.1 | -42.3 | -39.8 | -24.6 | — | 2 | BULLISH | 52.7 |
| PLSE Pulse Biosciences, Inc. | $3.8B | -44.9 | -78.5 | -1410.2 | -5681.3 | — | 3 | BULLISH | 194.2 |
| IRON Disc Medicine, Inc. | $2.9B | -12.1 | -39.1 | 1672.3 | — | — | 1 | BULLISH | -6.7 |
| BHVN Biohaven Ltd. | $2.1B | -3.3 | -799.5 | -1083.0 | — | — | 3 | BULLISH | -7.9 |
| ZYME Zymeworks Inc. | $2.0B | -14.3 | -72.3 | -156.9 | -980.8 | -69.8 | 2 | BULLISH | 62.6 |
| SAEYY Redcare Pharmacy N.V. | $1.7B | -37.3 | -8.7 | -1.2 | 0.6 | 20.5 | 2 | BULLISH | -5.2 |
| KMTS Kestra Medical Technologies, Ltd. | $1.7B | -11.3 | -73.7 | -113.5 | -142.3 | 191.6 | 3 | BULLISH | 15.3 |
| AGL Agilon Health, Inc. | $1.5B | -5.9 | -78.9 | -273.7 | 1.2 | 0.3 | 6 | BULLISH | 273.6 |
| NWKHY Netcare Limited | $1.4B | 12.5 | 16.9 | 8.1 | 6.7 | 5.0 | 7 | BULLISH | 59.5 |
| LBRX LB Pharmaceuticals Inc Common Stock | $1.2B | -13.4 | -25.8 | -768.9 | — | — | 2 | BULLISH | 148.2 |
| OABIW OmniAb, Inc. | $1.1B | -13.8 | -16.9 | -16.8 | -43.7 | 66.9 | 6 | BULLISH | -17.6 |
| ARRJF Arjo AB (publ) | $920M | 25.3 | 4.6 | 4.4 | 2.0 | -2.0 | 6 | BULLISH | 3.1 |
| RIGL Rigel Pharmaceuticals, Inc. | $900M | 2.8 | 126.9 | 88.5 | 22.0 | 3.3 | 4 | BULLISH | 68.7 |
| VMD Viemed Healthcare, Inc. | $370M | 25.7 | 10.2 | 11.8 | 3.5 | 25.2 | 4 | BULLISH | 39.9 |
| ONTTF Oxford Nanopore Technologies plc | $2.7B | -18.0 | -25.6 | -36.2 | -41.1 | 14.4 | 4 | BULLISH | 41.7 |
| EVH Evolent Health, Inc. | $540M | -1.0 | -79.0 | -1.8 | -4.3 | -4.5 | 5 | BULLISH | -43.4 |
| LYEL Lyell Immunopharma, Inc. | $230M | -0.6 | -93.3 | -227.7 | -1118875.0 | -55.0 | 3 | BULLISH | -42.6 |
| QDEL QuidelOrtho Corporation | $940M | -0.9 | -45.9 | -13.7 | -14.7 | 0.1 | 4 | BULLISH | -55.5 |
| PACB Pacific Biosciences of California, Inc. | $660M | -5.8 | -929.3 | -29.4 | -114.7 | 2.0 | 2 | BULLISH | 21.3 |
| NAUT Nautilus Biotechnolgy, Inc. | $410M | -6.5 | -41.0 | -89.2 | -6682.1 | — | 2 | BULLISH | 136.9 |
| ERAS Erasca, Inc. | $5.0B | -15.8 | -78.2 | -87.5 | — | — | 2 | BULLISH | 539.5 |
| RARE Ultragenyx Pharmaceutical Inc. | $1.5B | -2.9 | 839.4 | -67.5 | -43.0 | 17.5 | 2 | BULLISH | -50.0 |
| ESAIY Eisai Co., Ltd. | $9.2B | 34.0 | 3.8 | 3.3 | 7.8 | 248.0 | 6 | BULLISH | 9.7 |
| LGND Ligand Pharmaceuticals Incorporated | $6.0B | 31.2 | 22.0 | 11.3 | 76.2 | 54.9 | 5 | BULLISH | 66.7 |
| DSRLF DiaSorin S.p.A. | $4.4B | 25.1 | 14.2 | 8.9 | 14.0 | 46.3 | 5 | BULLISH | -2.4 |
| MAHLY MediPal Holdings Corporation | $4.1B | 15.1 | 7.5 | 8.7 | 1.4 | 5.9 | 7 | BULLISH | 23.9 |
| CDNA CareDx, Inc | $3.6B | 32.8 | 29.5 | -2.5 | 83.8 | 34.4 | 8 | BULLISH | 371.1 |
| CZMWY Carl Zeiss Meditec AG | $3.5B | 21.1 | 5.6 | 4.8 | 9.8 | 22.1 | 7 | BULLISH | -26.2 |
| BHC Bausch Health Companies Inc. | $2.4B | -2.1 | 86.8 | 12.2 | 9.0 | 10.5 | 5 | BULLISH | 1.8 |
| SZUKF Suzuken Co., Ltd. | $2.4B | 10.9 | 9.3 | 8.6 | 0.5 | 5.0 | 4 | BULLISH | 18.9 |
| ADUS Addus HomeCare Corporation | $2.3B | 21.3 | 9.7 | 9.6 | 7.3 | 15.9 | 6 | BULLISH | -0.3 |
| AUPH Aurinia Pharmaceuticals Inc. | $2.2B | 7.3 | 66.1 | 127.2 | 45.0 | 19.8 | 7 | BULLISH | 45.1 |
| XNCR Xencor, Inc. | $1.9B | -13.7 | -29.1 | -152.4 | -42.4 | -36.1 | 2 | BULLISH | 127.0 |
| TGLVY Top Glove Corporation Bhd. | $1.7B | 25.1 | 6.3 | 8.5 | 12.6 | 21.4 | 8 | BULLISH | 51.4 |
| TRAX First Tracks Biotherapeutics Inc | $1.6B | — | — | — | — | — | — | BULLISH | — |
| SLN Silence Therapeutics plc | $930M | -5.2 | -90.4 | 157.8 | — | -97.6 | 1 | BULLISH | 171.0 |
| BBNX Beta Bionics, Inc. | $860M | -13.0 | -26.2 | -79.6 | -73.1 | 191.1 | 3 | BULLISH | 2.1 |
| PBYI Puma Biotechnology, Inc. | $570M | 20.3 | 22.0 | 52.8 | 14.5 | -2.9 | 6 | BULLISH | 108.8 |
| CV CapsoVision, Inc. | $370M | -10.7 | -226.6 | -73.0 | -205.4 | — | 2 | BULLISH | 37.8 |
| SGMT Sagimet Biosciences Inc. | $310M | -8.2 | -24.4 | -231.4 | — | — | 3 | BULLISH | 14.0 |
| XRAY DENTSPLY SIRONA Inc. | $1.9B | -3.4 | -33.0 | 9.9 | 4.1 | -0.8 | 5 | BULLISH | -27.6 |
| IDGXF Integrated Diagnostics Holdings plc | $340M | 10.4 | 41.4 | 38.4 | 13.8 | 46.8 | 8 | BULLISH | 10.8 |
| NBTX Nanobiotix S.A. | $1.5B | -27.5 | 104.2 | 62.0 | -626.0 | 49.1 | 4 | BULLISH | 79.8 |
| LQDA Liquidia Corporation | $3.8B | 29.0 | 131.8 | 391.9 | 43.5 | 2233.6 | 6 | BULLISH | 103.0 |
| SNPHY Santen Pharmaceutical Co., Ltd. | $3.6B | 14.7 | 13.6 | 14.9 | 10.4 | 0.9 | 8 | BULLISH | 14.7 |
| SLS SELLAS Life Sciences Group, Inc. | $2.3B | -57.2 | -39.6 | 55646.0 | — | — | 4 | BULLISH | 511.6 |
| NTLA Intellia Therapeutics, Inc. | $1.6B | -3.6 | -55.4 | -92.1 | -1392.3 | 12.6 | 5 | BULLISH | -52.0 |
| CSTL Castle Biosciences, Inc. | $1.0B | -52.0 | -4.2 | -10.6 | -2.0 | 3.2 | 4 | BULLISH | 40.8 |
| PHAR Pharming Group N.V. | $710M | 81.8 | 3.6 | 3.2 | 1.8 | 7.8 | 7 | BULLISH | -12.7 |
| CARL Carlsmed, Inc. | $400M | -11.5 | -43.8 | -122.7 | -55.5 | — | 2 | BULLISH | 14.4 |
| HLUBF H. Lundbeck A/S | $7.3B | 13.4 | 15.2 | 12.6 | 17.6 | 10.1 | 7 | BULLISH | 22.5 |
| IOVA Iovance Biotherapeutics, Inc. | $6.4B | -20.1 | -40.4 | -49.1 | -47.6 | 34.5 | 6 | BULLISH | 548.0 |
| CNVVY ConvaTec Group Plc | $6.3B | 50.6 | 7.6 | 10.2 | 4.4 | 5.5 | 5 | BULLISH | -2.0 |
| KOD Kodiak Sciences Inc. | $5.5B | -21.7 | -368.4 | -630.1 | — | — | 1 | BULLISH | 388.6 |
| PCRX Pacira BioSciences, Inc. | $1.4B | 103.4 | 2.0 | 1.8 | 2.4 | 5.7 | 8 | BULLISH | 67.4 |
| KHTRF Knight Therapeutics Inc. | $810M | 76.5 | 1.9 | 2.6 | -2.3 | 42.4 | 8 | BULLISH | 98.5 |
| ATR AptarGroup, Inc. | $8.1B | 22.6 | 13.6 | 10.1 | 8.5 | 8.9 | 6 | BULLISH | -1.8 |
| AKBLF ALK-Abelló A/S | $7.4B | 39.9 | 21.2 | 23.9 | 18.9 | 16.4 | 8 | BULLISH | 12.8 |
| LVZPF Livzon Pharmaceutical Group Inc. | $6.1B | 16.0 | 11.5 | 16.4 | 15.3 | -14.4 | 4 | BULLISH | 0.0 |
| GRAL GRAIL Inc. | $5.9B | -15.7 | -16.1 | -24.9 | -246.7 | 23.1 | 5 | BULLISH | 68.5 |
| OPCH Option Care Health, Inc. | $4.7B | 23.5 | 16.0 | 10.6 | 3.7 | 5.9 | 5 | BULLISH | 12.1 |
| AMBBY Ambu A/S | $3.2B | 41.6 | 8.5 | 9.0 | 9.5 | -411.9 | 6 | BULLISH | -28.5 |
| PRVA Privia Health Group, Inc. | $2.9B | 97.1 | 0.0 | 0.0 | 1.4 | 24.1 | 1 | BULLISH | -16.0 |
| DRWKF Drägerwerk AG & Co. KGaA | $2.3B | 11.2 | 11.0 | 9.8 | 3.5 | 6.5 | 9 | BULLISH | 36.8 |
| OMCL Omnicell, Inc. | $1.7B | 42.8 | 3.1 | 3.2 | 7.8 | 8.5 | 9 | BULLISH | 18.2 |
| VTRLY Vitrolife AB (publ) | $1.4B | -3.1 | -46.2 | -41.3 | 14.3 | -2.0 | 5 | BULLISH | -34.0 |
| OPK OPKO Health, Inc. | $1.2B | -16.8 | -5.9 | -3.0 | -5.1 | -11.5 | 2 | BULLISH | 7.3 |
| EMBC Embecta Corp. | $380M | 4.4 | -13.6 | 26.3 | 7.8 | -7.6 | 5 | BULLISH | -53.7 |
| CASBF CanSino Biologics Inc. | $1.4B | 367.7 | 0.8 | -1.2 | 11.0 | 32.5 | 7 | BULLISH | -25.5 |
| REPL Replimune Group, Inc. | $1.1B | -4.2 | -134.3 | -1055.2 | — | — | 1 | BULLISH | 48.3 |
| OPHLY Ono Pharmaceutical Co., Ltd. | $7.4B | 15.2 | 9.5 | 11.3 | 20.8 | 3.3 | 9 | BULLISH | 29.5 |
| LIVN LivaNova PLC | $4.4B | 23.3 | 15.4 | 30.2 | 27.8 | 12.4 | 8 | BULLISH | 46.4 |
| LMAT LeMaitre Vascular, Inc. | $1.9B | 29.1 | 16.8 | 25.6 | 24.2 | 11.8 | 8 | BULLISH | -5.8 |
| ABSI Absci Corporation | $1.6B | -13.4 | -57.7 | -213.1 | -10443.4 | -62.3 | 5 | BULLISH | 147.5 |
| CRON Cronos Group Inc. | $1.2B | 18.0 | 6.5 | 5.4 | 60.5 | 72.9 | 7 | BULLISH | 34.1 |
| PRCT PROCEPT BioRobotics Corporation | $1.1B | -10.2 | -30.2 | -47.6 | -28.4 | 22.7 | 2 | BULLISH | -43.4 |
| CRMD CorMedix Inc. | $610M | 3.3 | 54.9 | 57.2 | 25.5 | 280.5 | 5 | BULLISH | -28.4 |
| IOBCF Ion Beam Applications S.A. | $550M | 19.7 | 20.6 | 14.0 | 2.9 | 7.0 | 5 | BULLISH | 39.5 |
| TCMD Tactile Systems Technology, Inc. | $540M | 21.4 | 11.9 | 13.8 | 9.1 | 17.2 | 8 | BULLISH | 55.4 |
| NRC NRC Health | $490M | 82.2 | 42.0 | 9.9 | -9.3 | -0.2 | 6 | BULLISH | 48.3 |
| SI Shoulder Innovations, Inc. | $410M | -11.6 | -28.2 | -69.1 | -59.1 | — | 1 | BULLISH | 57.7 |
| MTHRY M3, Inc. | $8.2B | 27.5 | 12.1 | 16.9 | 10.1 | 17.7 | 7 | BULLISH | -17.1 |
| XERS Xeris Biopharma Holdings, Inc. | $1.9B | -107.0 | 118.2 | 18.3 | -33.8 | 36.3 | 6 | BULLISH | 13.5 |
| ESTA Establishment Labs Holdings Inc. | $1.9B | -51.5 | -175.3 | -6.9 | -17.4 | 38.6 | 5 | BULLISH | 36.4 |
| EKTAY Elekta AB (publ) | $2.2B | -60.9 | -4.4 | -49.1 | 7.5 | -7.8 | 4 | BULLISH | 9.3 |
| BRKR Bruker Corporation | $8.8B | -86.2 | -3.4 | 3.0 | -6.2 | 1.6 | 6 | BULLISH | 55.9 |
| SKHHY Sonic Healthcare Limited | $6.5B | 15.5 | 7.3 | 6.2 | 6.2 | 52.7 | 5 | BULLISH | -5.9 |
| RDNT RadNet, Inc. | $5.5B | -277.5 | -2.1 | 1.8 | 1.2 | 18.9 | 5 | BULLISH | -11.8 |
| VOR Vor Biopharma Inc. | $990M | 0.1 | -73.6 | 22.2 | — | — | 3 | BULLISH | -28.1 |
| KMDA Kamada Ltd. | $450M | 21.0 | 8.4 | 11.0 | 16.9 | 13.2 | 7 | BULLISH | 17.2 |
| ALEC Alector, Inc. | $200M | -1.9 | -385.1 | 66.8 | -692.5 | -82.9 | 1 | BULLISH | 40.0 |
| RXRX Recursion Pharmaceuticals, Inc. | $2.0B | -3.9 | -56.6 | -99.7 | -1708.0 | -14.9 | 4 | BULLISH | -33.0 |
| PAHC Phibro Animal Health Corporation | $1.6B | 15.7 | 29.7 | 13.2 | 5.5 | 17.1 | 7 | BULLISH | -9.1 |
| KROS Keros Therapeutics, Inc. | $220M | -3.1 | -17.2 | -392.2 | — | -93.6 | 3 | BULLISH | -24.0 |
| IMCR Immunocore Holdings plc | $1.6B | -176.2 | -2.3 | -472.0 | -0.7 | 13.4 | 4 | BULLISH | -3.4 |
| CNMD CONMED Corporation | $1.5B | 25.3 | 5.5 | 5.2 | 6.7 | 3.4 | 7 | BULLISH | -1.3 |
| PNTG The Pennant Group, Inc. | $1.5B | 44.1 | 9.6 | 5.5 | 3.0 | 37.9 | 6 | BULLISH | 72.8 |
| DMAC DiaMedica Therapeutics Inc. | $470M | -11.9 | -114.6 | 616.3 | — | — | 2 | BULLISH | 26.3 |
| DMRA Damora Therapeutics, Inc. | $1.3B | — | — | — | — | — | — | BULLISH | — |
| MLTX MoonLake Immunotherapeutics | $1.0B | -3.1 | -67.4 | 2902.7 | — | — | 1 | BULLISH | 25.3 |
| COGT Cogent Biosciences, Inc. | $5.4B | -13.9 | -109.7 | 1964.0 | — | — | 3 | BULLISH | 111.6 |
| ALMR Alamar Biosciences, Inc. | $2.1B | — | — | — | — | — | — | BULLISH | — |
| SHWGF Shandong Weigao Group Medical Polymer Company Limited | $1.9B | 9.3 | 5.6 | 7.4 | 11.3 | 2.2 | 6 | BULLISH | -39.1 |
| JCRRF JCR Pharmaceuticals Co., Ltd. | $460M | 75.9 | 1.9 | -0.5 | -19.7 | 66.6 | 4 | BULLISH | -17.1 |
| SHTDF Sinopharm Group Co. Ltd. | $6.3B | 6.2 | 8.4 | 8.1 | 1.2 | -2.2 | 5 | BULLISH | -15.2 |
| SHPMY Shanghai Pharmaceuticals Holding Co., Ltd | $5.1B | 12.8 | 6.2 | 6.5 | 2.9 | 4.1 | 5 | BULLISH | -13.8 |
| RLAY Relay Therapeutics, Inc. | $4.0B | -12.0 | -36.8 | -2519.7 | -23916.3 | 23.9 | 4 | BULLISH | 174.6 |
| EDIT Editas Medicine, Inc. | $370M | -3.4 | -118.8 | 71.4 | -153.3 | 20.8 | 4 | BULLISH | -30.1 |
| APNHY Aspen Pharmacare Holdings Limited | $4.2B | 26.9 | 3.2 | 5.3 | 6.6 | -20.1 | 7 | BULLISH | 69.4 |
| DYN Dyne Therapeutics, Inc. | $2.9B | -5.1 | -81.6 | 240.4 | — | — | 2 | BULLISH | -1.1 |
| CSWYF China Shineway Pharmaceutical Group Limited | $760M | 6.0 | 19.9 | 46.7 | 21.6 | 1081.8 | 8 | BULLISH | 0.0 |
| ITGR Integer Holdings Corporation | $4.3B | 34.3 | 7.5 | 5.4 | 5.1 | 2.6 | 7 | BULLISH | 73.8 |
| ACHC Acadia Healthcare Company, Inc. | $2.9B | -2.4 | -44.5 | 6.1 | 1.3 | 4.3 | 4 | BULLISH | 27.8 |
| PTGX Protagonist Therapeutics, Inc. | $9.0B | 115.5 | 11.0 | 84.1 | 76.3 | 34.8 | 7 | LEAN BULL | 88.5 |
| SHC Sotera Health Company | $5.2B | 32.2 | 27.8 | 10.6 | 16.7 | 8.1 | 7 | LEAN BULL | 9.7 |
| DFTX Definium Therapeutics, Inc. | $4.8B | -10.8 | -25.7 | 82.4 | — | — | 2 | LEAN BULL | — |
| SOPH SOPHiA GENETICS S.A. | $630M | -6.7 | -101.2 | -155.2 | -95.9 | 23.6 | 3 | LEAN BULL | 77.4 |
| NGNE Neurogene Inc. | $370M | -4.9 | -45.3 | -111469.0 | — | — | 2 | LEAN BULL | -9.7 |
| BCYC Bicycle Therapeutics plc | $250M | -1.4 | -32.3 | -1197.0 | -8002.1 | 217.4 | 4 | LEAN BULL | -52.0 |
| LCTX Lineage Cell Therapeutics, Inc. | $250M | -7.3 | -59.0 | -171.3 | 138.6 | 19.9 | 5 | LEAN BULL | -39.4 |
| CHEOY Cochlear Limited | $6.7B | 62.1 | 7.8 | 11.6 | -1.2 | -1.2 | 6 | LEAN BULL | -48.2 |
| NVST Envista Holdings Corp | $3.8B | 40.2 | 3.1 | 3.2 | 7.4 | 11.9 | 7 | LEAN BULL | 15.9 |
| SGHT Sight Sciences, Inc. | $500M | -16.1 | -48.4 | -145.7 | -19.0 | 9.3 | 4 | LEAN BULL | 71.0 |
| PTCHF PureTech Health plc | $390M | 157.1 | 0.2 | 50.8 | 1890.6 | 7.7 | 4 | LEAN BULL | -5.4 |
| OBIO Orchestra BioMed Holdings, Inc. | $340M | -5.6 | -397.3 | 468.3 | -26994.3 | 986.1 | 4 | LEAN BULL | 46.0 |
| USPH U.S. Physical Therapy, Inc. | $1.3B | 511.8 | -1.3 | 7.7 | 0.7 | 17.1 | 5 | LEAN BULL | -3.7 |
| SDGCF Sundrug Co.,Ltd. | $3.3B | 13.5 | 11.4 | 10.6 | 3.7 | 4.9 | 6 | LEAN BULL | 0.0 |
| ARHCF Alfresa Holdings Corporation | $2.5B | 11.4 | 5.7 | 7.8 | 0.2 | 3.6 | 5 | LEAN BULL | 17.9 |
| TSMRF Tsumura & Co. | $1.7B | 9.2 | 9.9 | 6.6 | 13.0 | 10.7 | 4 | LEAN BULL | 0.0 |
| SWGHF Sawai Group Holdings Co., Ltd. | $1.3B | 22.7 | 4.3 | 4.6 | 4.7 | 11.4 | 4 | LEAN BULL | 0.0 |
| TWAPF Towa Pharmaceutical Co., Ltd. | $1.3B | 21.1 | 4.7 | 3.2 | 7.7 | 7.1 | 7 | LEAN BULL | 54.4 |
| KKPCF Kaken Pharmaceutical Co., Ltd. | $980M | 14.0 | 6.9 | 7.9 | 28.0 | -6.6 | 4 | LEAN BULL | 8.3 |
| INSP Inspire Medical Systems, Inc. | $2.1B | 15.2 | 18.0 | 19.7 | 0.2 | 4.3 | 8 | LEAN BULL | -7.9 |
| VREX Varex Imaging Corporation | $780M | 35.1 | 4.6 | 7.6 | 7.5 | 5.3 | 6 | LEAN BULL | 54.0 |
| ELVN Enliven Therapeutics, Inc. | $3.0B | -26.5 | -15.3 | -6535.0 | — | — | 3 | LEAN BULL | 112.0 |
| NEOG Neogen Corporation | $2.7B | -49.3 | -2.7 | -0.2 | -5.3 | -0.3 | 7 | LEAN BULL | 101.5 |
| PHVS Pharvaris N.V. | $2.2B | -10.6 | -70.7 | 860.9 | — | — | 4 | LEAN BULL | 39.0 |
| STOK Stoke Therapeutics, Inc. | $1.6B | -7.8 | -61.1 | -318.5 | -660.8 | -86.2 | 2 | LEAN BULL | -19.1 |
| CERS Cerus Corporation | $470M | -67.3 | -10.8 | -7.4 | -5.1 | 15.1 | 5 | LEAN BULL | 56.9 |
| CCCC C4 Therapeutics, Inc. | $380M | -3.2 | -48.1 | -175.0 | -355.9 | 2.3 | 4 | LEAN BULL | 31.0 |
| ZURA Zura Bio Limited | $320M | -3.8 | -65.4 | 806.5 | — | — | 2 | LEAN BULL | 15.7 |
| INNV Innovage Holding Corp. | $1.3B | -439.5 | -1.1 | -89.6 | 3.2 | 16.4 | 6 | LEAN BULL | 73.1 |
| COLL Collegium Pharmaceutical, Inc. | $750M | 15.0 | 17.6 | 9.4 | -7.5 | 14.3 | 6 | LEAN BULL | -34.8 |
| PRLD Prelude Therapeutics Incorporated | $210M | -4.9 | -57.7 | 14236.3 | -244.1 | 220.3 | 5 | LEAN BULL | 139.5 |
| BRVE Braveheart Bio, Inc. | $1.5B | — | — | — | — | — | — | LEAN BULL | — |
| SRZN Surrozen, Inc. | $190M | -0.7 | 387.2 | 11.1 | 1003.5 | -8.8 | 2 | LEAN BULL | 114.8 |
| GMRS GMR Solutions Inc. | $580M | — | — | — | — | — | — | LEAN BULL | — |
| CYDY CytoDyn Inc. | $380M | -4.9 | 57.8 | 24.6 | — | 100.0 | 4 | LEAN BULL | -16.2 |
| ALBHF Alibaba Health Information Technology Limited | $6.3B | 19.9 | 11.2 | 20.8 | 3.8 | -36.2 | 3 | LEAN BULL | -50.2 |
| PVLA Palvella Therapeutics, Inc. | $1.8B | -27.4 | -46.6 | 137.5 | — | — | 3 | LEAN BULL | 82.1 |
| TYRA Tyra Biosciences, Inc. | $1.2B | -8.9 | -45.3 | -2390.9 | — | — | 2 | LEAN BULL | 51.2 |
| STLN Starling Oncology, Inc. | $670M | — | — | — | — | — | — | LEAN BULL | — |
| PRTA Prothena Corporation plc | $420M | -10.5 | -14.4 | -871.5 | -1839.9 | 427.3 | 5 | LEAN BULL | -10.3 |
| ENTA Enanta Pharmaceuticals, Inc. | $340M | -5.0 | -70.1 | 141.5 | -135.8 | 0.7 | 4 | LEAN BULL | 15.9 |
| GLSI Greenwich LifeSciences, Inc. | $240M | -11.0 | -951.6 | 299.9 | — | — | 2 | LEAN BULL | 74.4 |
| BEAM Beam Therapeutics Inc. | $2.5B | -30.2 | -8.1 | -184.5 | -25036.3 | 158.9 | 4 | LEAN BULL | -10.9 |
| NEO NeoGenomics, Inc. | $2.2B | -43.6 | -6.3 | -4.8 | 1.1 | 11.2 | 5 | LEAN BULL | 61.9 |
| ATEC Alphatec Holdings, Inc. | $1.7B | -15.2 | -623.1 | -7.6 | -12.1 | 19.5 | 5 | LEAN BULL | -32.5 |
| IUSDF AS ONE Corporation | $1.0B | 19.2 | 12.2 | 13.4 | 8.1 | 5.7 | 6 | LEAN BULL | -39.5 |
| SRPT Sarepta Therapeutics, Inc. | $1.9B | -13.0 | -9.5 | -6.3 | -1.2 | -20.4 | 4 | NEUTRAL | -17.2 |
| MLAB Mesa Laboratories, Inc. | $720M | 150.7 | 2.7 | 4.4 | 4.7 | 3.0 | 8 | NEUTRAL | 63.6 |
| OFIX Orthofix Medical Inc. | $400M | -6.4 | -13.9 | -3.6 | -7.5 | 3.0 | 6 | NEUTRAL | -39.2 |
| MSMKF MatsukiyoCocokara & Co. | $5.8B | 18.0 | 11.1 | 12.6 | 5.1 | 5.7 | 8 | NEUTRAL | -16.3 |
| ICUI ICU Medical, Inc. | $4.2B | 136.5 | 1.4 | 2.7 | 3.5 | -9.0 | 6 | NEUTRAL | 32.2 |
| CLCGY Clicks Group Limited | $3.1B | 15.8 | 47.7 | 39.1 | 6.5 | 6.3 | 6 | NEUTRAL | -37.3 |
| AVAH Aveanna Healthcare Holdings Inc. | $2.9B | 9.6 | 199.1 | 30.4 | 6.0 | 20.3 | 6 | NEUTRAL | 34.7 |
| NPNKF Nippon Shinyaku Co., Ltd. | $1.6B | 7.2 | 11.6 | 12.5 | 20.6 | 12.8 | 4 | NEUTRAL | -1.1 |
| ANAB AnaptysBio, Inc. | $1.5B | 7.3 | -1146.3 | 466.0 | 668.9 | 92.9 | 5 | NEUTRAL | 112.3 |
| OSCR Oscar Health, Inc. | $8.0B | 18.4 | 34.3 | -9.6 | 7.4 | 42.8 | 7 | NEUTRAL | 62.6 |
| KYKOF Kyowa Kirin Co., Ltd. | $8.1B | 15.6 | 9.3 | 14.2 | 12.8 | 7.4 | 7 | NEUTRAL | -9.5 |
| PMI Picard Medical, Inc. | $730M | -0.3 | -1631.2 | -469.0 | -191.6 | — | 2 | NEUTRAL | 28.2 |
| BCHMF Bachem Holding AG | $6.8B | 41.9 | 10.6 | 8.2 | 15.4 | 4.3 | 3 | NEUTRAL | 24.7 |
| BUHPF Bumrungrad Hospital Public Company Limited | $4.8B | 21.0 | 27.3 | 37.3 | 30.3 | 1.6 | 5 | NEUTRAL | 23.7 |
| ANSLY Ansell Limited | $4.7B | 22.3 | 10.6 | 9.5 | 10.8 | 7.1 | 8 | NEUTRAL | 43.8 |
| TCHBF Tecan Group AG | $3.5B | -26.5 | -9.7 | 2.8 | 2.9 | -4.2 | 6 | NEUTRAL | 45.2 |
| OSSFF Embla Medical hf. | $1.9B | 18.0 | 10.4 | 7.7 | 10.5 | 9.9 | 7 | NEUTRAL | -5.6 |
| CSSPF NIOX Group Plc | $380M | 41.3 | 10.8 | 13.0 | 24.6 | 3.5 | 7 | NEUTRAL | -2.3 |
| SABS SAB Biotherapeutics, Inc. | $260M | 0.9 | -11.3 | -48.4 | — | -100.0 | 3 | NEUTRAL | 1.3 |
| NWBO Northwest Biotherapeutics, Inc. | $260M | -6.7 | 55.8 | -188.7 | -1142.6 | 98.6 | 3 | NEUTRAL | -33.7 |
| TXG 10x Genomics, Inc. | $9.3B | -132.5 | -9.4 | -19.8 | -11.9 | -4.3 | 5 | NEUTRAL | 466.6 |
| ABCL AbCellera Biologics Inc. | $3.8B | -23.5 | -17.3 | -36.2 | -1368.6 | 101.3 | 4 | NEUTRAL | 126.7 |
| PSNL Personalis, Inc. | $1.7B | -14.7 | -50.3 | -149.3 | -141.7 | -13.3 | 2 | NEUTRAL | 65.1 |
| HUMDF Hua Medicine (Shanghai) Ltd. | $300M | -17.8 | -10.3 | -30.2 | -8.0 | 73.9 | 3 | NEUTRAL | -26.1 |
| LYCA Lycia Therapeutics Inc. | $1.6B | — | — | — | — | — | — | N/A | — |
| NUTX Nutex Health, Inc. | $1.4B | 7.8 | 49.2 | 53.9 | 31.2 | 6.9 | 7 | NEUTRAL | 65.8 |
| CTY City Therapeutics Inc. | $200M | — | — | — | — | — | — | N/A | — |
| TSUSF Tsuruha Holdings Inc. | $4.2B | 17.4 | 6.2 | 12.0 | 2.8 | 16.1 | 5 | NEUTRAL | 0.0 |
| JANX Janux Therapeutics, Inc. | $1.0B | -10.4 | -10.7 | 516.9 | -214.0 | 7162.0 | 4 | NEUTRAL | -30.7 |
| VHIBF Vitalhub Corp. | $340M | 62.2 | 3.3 | 10.7 | 6.1 | 53.9 | 7 | NEUTRAL | -31.4 |
| ODTX Odyssey Therapeutics, Inc. | $940M | — | — | — | — | — | — | NEUTRAL | — |
| DRUG Bright Minds Biosciences Inc. | $520M | -26.2 | -13.7 | -105758.3 | — | — | 3 | NEUTRAL | -11.7 |
| DNPUF Sumitomo Pharma Co., Ltd. | $6.4B | 6.9 | 39.1 | 10.3 | 13.1 | 14.5 | 6 | NEUTRAL | 5.6 |
| SGFEF Siegfried Holding AG | $3.9B | 19.2 | 17.0 | 9.4 | 10.8 | 3.4 | 4 | NEUTRAL | -15.8 |
| PHMMF Pharma Mar, S.A. | $1.6B | 21.2 | 24.9 | 35.9 | -2.0 | 15.5 | 7 | NEUTRAL | 1.7 |
| RKAGY RHÃN-KLINIKUM Aktiengesellschaft | $1.1B | 22.3 | 2.8 | 3.1 | 2.1 | 2.5 | 6 | NEUTRAL | 10.7 |
| ADPT Adaptive Biotechnologies Corporation | $4.1B | -68.5 | -39.6 | -14.1 | -55.6 | 50.1 | 5 | NEUTRAL | 60.6 |
| OGN Organon & Co. | $3.6B | 17.4 | 24.0 | 6.0 | 6.9 | -2.5 | 5 | NEUTRAL | 50.4 |
| CHE Chemed Corporation | $6.7B | 25.4 | 27.1 | 23.2 | 10.1 | 3.3 | 6 | NEUTRAL | 16.6 |
| ZLAB Zai Lab Limited | $2.7B | -13.3 | -26.9 | -85.4 | -47.8 | 5.1 | 3 | NEUTRAL | -10.4 |
| UFPT UFP Technologies, Inc. | $2.3B | 31.4 | 17.1 | 13.3 | 12.0 | 7.3 | 7 | NEUTRAL | 46.7 |
| ZBIO Zenas BioPharma, Inc. | $1.8B | -2.9 | -199.0 | 5842.1 | -11145.6 | -93.3 | 2 | NEUTRAL | 14.2 |
| FLGT Fulgent Genetics, Inc. | $550M | -7.3 | -8.0 | -12.6 | -34.6 | 6.8 | 4 | NEUTRAL | -12.8 |
| VCRE Vicore Pharma Holding AB | $260M | — | — | — | — | — | — | NEUTRAL | — |
| RYTM Rhythm Pharmaceuticals, Inc. | $6.2B | -29.5 | -200.0 | 144.2 | -69.2 | 53.5 | 4 | NEUTRAL | -16.6 |
| AMPH Amphastar Pharmaceuticals, Inc. | $1.1B | 14.6 | 10.3 | 7.5 | 16.5 | 1.4 | 6 | NEUTRAL | 4.3 |
| PBH Prestige Consumer Healthcare Inc. | $2.3B | 13.2 | 9.1 | 5.5 | 11.0 | -1.4 | 4 | LEAN BEAR | -23.8 |
| AHCO AdaptHealth Corp. | $820M | -3.5 | -15.5 | -0.2 | -18.1 | 22.9 | 6 | LEAN BEAR | -37.6 |
| MCTA Charming Medical Limited Class A Ordinary Shares | $450M | — | — | — | — | — | — | LEAN BEAR | — |
| AHICF Asahi Intecc Co., Ltd. | $5.7B | 30.5 | 20.0 | 27.8 | 14.6 | 21.6 | 9 | LEAN BEAR | 32.6 |
| GEDSF Gedeon Richter PLC | $4.5B | 10.7 | 16.4 | 22.0 | 29.6 | 4.8 | 7 | LEAN BEAR | 0.0 |
| GLPGF Lakefront Biotherapeutics | $2.1B | 3.8 | 20.2 | 39.4 | 17.4 | 259.3 | 5 | LEAN BEAR | -4.5 |
| STSEY Stratec SE | $1.7B | -575.0 | -0.2 | -0.2 | 7.0 | -4.8 | 4 | LEAN BEAR | -17.8 |
| SAFLY Safilo Group S.p.A. | $1.4B | 15.4 | 12.0 | 10.0 | 8.7 | -3.4 | 7 | LEAN BEAR | 40.1 |
| AGYTF Allergy Therapeutics plc | $760M | -4.3 | 3372.3 | -97.9 | -54.9 | 19.9 | 3 | LEAN BEAR | 36.4 |
| INRLF Valneva SE | $640M | -2.8 | -118.0 | -54.8 | -89.3 | -27.2 | 1 | LEAN BEAR | -25.4 |
| BDULF Bangkok Dusit Medical Services Public Company Limited | $9.7B | 20.7 | 15.0 | 12.4 | 12.1 | 1.3 | 4 | LEAN BEAR | -3.2 |
| NPCE NeuroPace, Inc. | $440M | -23.0 | -122.1 | -39.6 | -27.2 | 11.6 | 4 | LEAN BEAR | 24.2 |
| LNTH Lantheus Holdings, Inc. | $6.5B | 23.8 | 22.2 | 17.1 | 19.3 | 2.3 | 5 | LEAN BEAR | 78.7 |
| EWTX Edgewise Therapeutics, Inc. | $4.2B | -21.4 | -38.0 | 1912.5 | — | — | 1 | LEAN BEAR | 160.4 |
| AORT Artivion, Inc. | $1.1B | -386.5 | -0.7 | -3.4 | -10.7 | 16.4 | 4 | LEAN BEAR | -47.1 |
| RSLBF RaySearch Laboratories AB (publ) | $510M | 31.8 | 26.1 | 21.8 | 7.2 | 1.2 | 6 | LEAN BEAR | -35.8 |
| COGZF Cogstate Limited | $410M | 34.6 | 22.4 | 37.3 | 22.4 | -14.8 | 3 | LEAN BEAR | 44.9 |
| SLGL Sol-Gel Technologies Ltd. | $230M | -12.4 | -35.9 | -228.0 | 36.4 | 282.9 | 3 | LEAN BEAR | 74.8 |
| SRRK Scholar Rock Holding Corporation | $5.0B | -12.8 | -167.8 | 931.3 | — | — | 2 | LEAN BEAR | 43.2 |
| ACAD Acadia Pharmaceuticals Inc. | $3.4B | 9.0 | 35.7 | 63.9 | 10.2 | 11.8 | 5 | LEAN BEAR | -8.4 |
| CLOV Clover Health Investments, Corp. | $2.4B | -114.2 | -5.1 | -8.3 | 3.8 | 54.0 | 4 | LEAN BEAR | 21.2 |
| JBIO Jade Biosciences, Inc. | $930M | -5.4 | -47.8 | 629.9 | — | — | 3 | LEAN BEAR | 47.4 |
| CGEM Cullinan Therapeutics, Inc. | $880M | -4.4 | -50.3 | 1635.6 | — | — | 1 | LEAN BEAR | 91.2 |
| ACRS Aclaris Therapeutics, Inc. | $550M | -6.6 | -59.1 | -206.5 | -1320.1 | -51.0 | 3 | LEAN BEAR | 76.3 |
| ANGO AngioDynamics, Inc. | $520M | -15.4 | -19.2 | -20.5 | -8.8 | 8.2 | 5 | LEAN BEAR | -0.7 |
| SRTA Strata Critical Medical, Inc. | $410M | 9.5 | 16.0 | -6.2 | -14.5 | 0.6 | 3 | LEAN BEAR | -6.2 |
| IFRX InflaRx N.V. | $230M | -3.0 | -38.5 | 251.5 | — | -106.2 | 4 | LEAN BEAR | 18.6 |
| JNDOF JINS HOLDINGS Inc. | $810M | 17.8 | 22.7 | 27.1 | 5.1 | 15.0 | 6 | LEAN BEAR | 51.6 |
| HNGZY Hangzhou Tigermed Consulting Co., Ltd | $6.9B | 597.8 | 0.5 | 1.6 | -24.2 | 12.0 | 6 | LEAN BEAR | 11.2 |
| SHJBF Shanghai Junshi Biosciences Co., Ltd. | $4.8B | -69.3 | -7.1 | -6.3 | 4.4 | 29.7 | 5 | LEAN BEAR | -20.8 |
| MCVEF Medicover AB (publ) | $4.1B | 44.6 | 16.9 | 6.8 | 3.8 | 9.4 | 7 | LEAN BEAR | 0.0 |
| ADRX ADARx Pharmaceuticals, Inc. | $1.9B | — | — | — | — | — | — | LEAN BEAR | — |
| MDRSF Medartis Holding AG | $1.4B | 78.9 | 5.5 | 0.7 | 3.2 | 29.6 | 6 | LEAN BEAR | 72.5 |
| HSTC HST Global, Inc. | $210M | -538.5 | -2.5 | -1.2 | -13.7 | 564.0 | 5 | LEAN BEAR | 349900.0 |
| MIRM Mirum Pharmaceuticals, Inc. | $5.2B | -5.9 | -703.0 | -27.3 | -38.1 | 44.0 | 3 | LEAN BEAR | 22.2 |
| CELC Celcuity Inc. | $3.2B | -16.0 | -1433.7 | 1325.2 | — | — | 3 | LEAN BEAR | -4.1 |
| DBVT DBV Technologies S.A. | $230M | -2.6 | -142.6 | -2201.5 | — | -100.0 | 2 | LEAN BEAR | -34.3 |
| FENC Fennec Pharmaceuticals Inc. | $350M | -81.5 | -18.6 | -76.2 | 11.0 | 77.8 | 6 | LEAN BEAR | 18.1 |
| TWST Twist Bioscience Corporation | $9.2B | -71.7 | -29.6 | -29.2 | -29.6 | 19.2 | 2 | LEAN BEAR | 368.6 |
| INBX Inhibrx Biosciences Inc. | $1.4B | -11.2 | -1773.6 | 55.8 | — | -100.0 | 4 | LEAN BEAR | 67.0 |
| LJUIF SSY Group Limited | $1.2B | 15.2 | 6.7 | 4.6 | 13.6 | -4.4 | 5 | LEAN BEAR | 0.0 |
| KARD Kardigan, Inc. | $1.1B | — | — | — | — | — | — | LEAN BEAR | — |
| SHEZF Shenzhen Hepalink Pharmaceutical Group Co., Ltd. | $690M | 64.9 | 2.8 | 2.7 | 7.0 | -0.3 | 6 | LEAN BEAR | 0.0 |
| YDES YD Bio Limited Ordinary Shares | $350M | — | — | — | — | — | — | LEAN BEAR | -64.9 |
| FATE Fate Therapeutics, Inc. | $250M | -2.0 | -60.7 | -140.1 | -1448.6 | -23.4 | 2 | LEAN BEAR | 115.1 |
| PTKFF PT Kalbe Farma Tbk. | $2.0B | 8.9 | 15.4 | 17.6 | 9.1 | 13.2 | 5 | LEAN BEAR | -18.5 |
| JXFGF Jinxin Fertility Group Limited | $730M | 26.4 | 1.9 | 1.8 | 7.8 | 1.4 | 7 | LEAN BEAR | 3.6 |
| FGHQF Frontage Holdings Corporation | $360M | 36.5 | 3.1 | 3.0 | 4.6 | 9.8 | 7 | LEAN BEAR | 16.8 |
| GWIN Glorywin Entertainment Group, Inc. | $360M | -26081.4 | 11.7 | 5.1 | — | — | 1 | LEAN BEAR | 229.5 |
| CLVSF CellaVision AB (publ) | $330M | 31.6 | 15.1 | 17.1 | 16.3 | -1.9 | 6 | LEAN BEAR | -27.4 |
| NURPF Neuren Pharmaceuticals Limited | $1.8B | 118.1 | 6.2 | 22.4 | 14.6 | -68.5 | 5 | LEAN BEAR | 20.8 |
| BJTRF Beijing Tong Ren Tang Chinese Medicine Company Limited | $540M | 10.3 | 20.8 | 23.4 | 32.9 | 697.9 | 9 | LEAN BEAR | 0.0 |
| IMNM Immunome, Inc. | $2.1B | -7.4 | -64.0 | -2208.4 | — | -100.0 | 4 | LEAN BEAR | 19.6 |
| ASTH Astrana Health, Inc. | $1.9B | 44.5 | 5.1 | 4.7 | 2.0 | 58.9 | 5 | LEAN BEAR | 10.9 |
| CLHLF COLTENE Holding AG | $330M | 19.7 | 16.1 | 12.5 | 3.6 | -2.5 | 5 | LEAN BEAR | -8.4 |
| XENE Xenon Pharmaceuticals Inc. | $3.4B | -7.6 | -43.6 | -109.7 | — | -100.0 | 3 | BEARISH | -11.7 |
| TSHA Taysha Gene Therapies, Inc. | $1.3B | -10.1 | -47.1 | 961.0 | — | -32.3 | 3 | BEARISH | -10.5 |
| MDRX Veradigm Inc. | $830M | -7.1 | 4.3 | 7.0 | 6.2 | -39.7 | 5 | BEARISH | 0.0 |
| ARVN Arvinas, Inc. | $470M | 39.1 | 1.6 | -519.3 | 67.8 | -15.0 | 4 | BEARISH | -19.1 |
| CAMP CAMP4 Therapeutics Corporation | $210M | -1.6 | -545.9 | 48.4 | -1884.8 | 40.2 | 2 | BEARISH | -1.9 |
| STVN Stevanato Group S.p.A. | $5.3B | 36.1 | 9.1 | 7.2 | 7.6 | 6.7 | 6 | BEARISH | -24.8 |
| ALVOW Alvotech | $3.9B | -8.1 | 98.5 | 3.3 | -63.2 | -12.2 | 0 | BEARISH | -85.2 |
| AXGN AxoGen, Inc. | $2.2B | -56.1 | -18.2 | -5.6 | -2.2 | 23.6 | 4 | BEARISH | 106.2 |
| SNBIF SanBio Company Limited | $1.3B | -19.5 | -55.8 | -2935.2 | — | — | 3 | BEARISH | 0.0 |
| CVSGF CVS Group plc | $1.1B | 52.6 | 5.9 | 7.3 | 2.7 | -22.7 | 6 | BEARISH | 0.7 |
| PKBFF PeakBirch Commerce Inc. | $540M | -0.0 | -16609.0 | 16544.6 | -58.8 | -69.1 | 3 | BEARISH | 0.0 |
| OVID Ovid Therapeutics Inc. | $420M | -4.7 | -26.0 | -43.7 | -2047.6 | -76.2 | 3 | BEARISH | 38.6 |
| CYH Community Health Systems, Inc. | $410M | -1.2 | 19.9 | -79.1 | 1.7 | 77.2 | 5 | BEARISH | -30.7 |
| RZLT Rezolute, Inc. | $370M | -5.4 | -59.0 | 1060.6 | — | — | 2 | BEARISH | -55.3 |
| TNGX Tango Therapeutics, Inc. | $3.9B | -27.3 | -21.3 | -253.2 | — | 121.5 | 3 | BEARISH | 205.2 |
| HCM HUTCHMED (China) Limited | $2.6B | 149.4 | 46.6 | 11.0 | 5.7 | -11.8 | 6 | BEARISH | -6.5 |
| GRDN Guardian Pharmacy Services, Inc. | $2.5B | 37.6 | 31.7 | 33.2 | 6.2 | 10.3 | 7 | BEARISH | 38.8 |
| TRVI Trevi Therapeutics, Inc. | $1.8B | -39.6 | -19.7 | -1451.7 | — | — | 3 | BEARISH | 27.0 |
| QURE uniQure N.V. | $1.6B | -5.9 | -157.6 | 37.9 | -1387.8 | 30.2 | 4 | BEARISH | -60.2 |
| BPMUF Basilea Pharmaceutica AG | $960M | 16.9 | 39.5 | 75.9 | 23.5 | 4.5 | 7 | BEARISH | 27.1 |
| DNA Ginkgo Bioworks Holdings, Inc. | $670M | -2.3 | -56.3 | -44.0 | -231.7 | -51.5 | 2 | BEARISH | -16.9 |
| BOIRF Boiron S.A. | $550M | 12.7 | 7.2 | 7.8 | 2.0 | 97.0 | 5 | BEARISH | 10.5 |
| CTEV Claritev Corporation | $400M | -1.4 | 169.3 | 0.9 | -23.0 | 110.3 | 4 | BEARISH | -67.5 |
| PANHF Ping An Healthcare and Technology Company Limited | $2.1B | 20.7 | 4.6 | 5.6 | 8.8 | 2.9 | 6 | BEARISH | -61.7 |
| RAPP Rapport Therapeutics, Inc. Common Stock | $1.2B | -9.1 | -40.0 | 3981.5 | — | — | 4 | BEARISH | 6.2 |
| RYHTY Ryman Healthcare Limited | $1.0B | -10.8 | -4.2 | -0.3 | -30.8 | 10.6 | 7 | BEARISH | -23.4 |
| MEOBF Mesoblast Limited | $2.0B | -29.4 | -9.9 | -14.4 | -23.4 | 613.8 | 5 | BEARISH | -20.0 |
| BIOGY BioGaia AB (publ) | $1.3B | 32.0 | 31.8 | 52.6 | 27.5 | 13.1 | 5 | BEARISH | 19.9 |
| PRAX Praxis Precision Medicines, Inc. | $7.1B | -20.8 | -38.9 | -51.2 | — | -100.0 | 4 | BEARISH | 53.8 |
| RGC Regencell Bioscience Holdings Limited | $3.8B | -311.9 | -128.5 | 1692.4 | — | — | 3 | BEARISH | -53.1 |
| CLDX Celldex Therapeutics, Inc. | $2.3B | -6.9 | -43.9 | -13685.9 | -334104.5 | -98.1 | 1 | BEARISH | 12.8 |
| BCRX BioCryst Pharmaceuticals, Inc. | $1.9B | -5.6 | 87.8 | 62.3 | 35.9 | 68.7 | 5 | BEARISH | 12.5 |
| TRLV Trulieve Cannabis Corp. | $1.8B | — | — | — | — | — | — | BEARISH | — |
| LYPHF Luye Pharma Group Ltd. | $1.1B | 7.8 | 4.5 | 6.7 | 13.0 | -2.1 | 6 | BEARISH | 0.8 |
| HROW Harrow Health, Inc. | $1.1B | -29.5 | -114.8 | 1.9 | -24.4 | 21.1 | 5 | BEARISH | -24.5 |
| APMD Apnimed, Inc. | $790M | — | — | — | — | — | — | BEARISH | — |
| STTK Shattuck Labs, Inc. | $550M | -11.4 | -39.2 | -29.3 | — | -66.6 | 4 | BEARISH | 200.5 |
| BNTC Benitec Biopharma Inc. | $300M | -8.9 | -33.2 | 1840.8 | — | — | 3 | BEARISH | -35.5 |
| ELDN Eledon Pharmaceuticals, Inc. | $190M | -2.4 | -110.7 | 411.1 | — | — | 2 | BEARISH | -30.8 |
| PPTDF PeptiDream Inc. | $870M | -38.0 | -7.1 | -9.6 | -25.7 | 47.8 | 4 | BEARISH | -38.7 |
| HSIC Henry Schein, Inc. | $9.5B | 24.3 | 12.2 | 8.7 | 2.7 | 6.5 | 7 | BEARISH | 32.0 |
| CSMYF COSMOS Pharmaceutical Corporation | $3.2B | 15.6 | 11.7 | 9.8 | 2.9 | 9.5 | 6 | BEARISH | -13.4 |
| WGS GeneDx Holdings Corp. | $1.7B | -17.2 | -40.8 | -17.2 | -15.5 | 25.4 | 4 | BEARISH | -51.3 |
| CSPHF CStone Pharmaceuticals | $1.4B | -14.4 | -51.4 | -340.2 | -123.0 | 135.6 | 5 | BEARISH | -15.4 |
| DRTSW Alpha Tau Medical Ltd. | $1.2B | -13.0 | -141.7 | -17.1 | — | — | 3 | BEARISH | 807.7 |
| OMDA Omada Health | $1.2B | 284.8 | 1.8 | -1.5 | 6.0 | 404.7 | 7 | BEARISH | -26.5 |
| SMSZF SMS Co., Ltd. | $700M | -14.9 | -40.8 | 31.1 | 18.4 | 6.9 | 6 | BEARISH | 0.0 |
| ZRSEF DocMorris AG | $520M | -10.1 | -30.1 | -29.3 | -8.9 | 11.0 | 2 | BEARISH | 0.0 |
| DCTH Delcath Systems, Inc. | $500M | 1344.2 | 0.5 | -2.7 | 9.2 | 35.8 | 6 | BEARISH | 44.2 |
| EOLS Evolus, Inc. | $460M | -14.2 | 138.6 | -20.7 | -9.6 | 13.9 | 5 | BEARISH | 8.5 |
| EBS Emergent BioSolutions Inc. | $320M | -1.9 | -40.3 | -5.5 | -76.9 | -9.6 | 5 | BEARISH | -31.5 |
| NHNKY Nihon Kohden Corporation | $3.1B | 19.1 | 7.8 | 7.9 | -1.6 | 2.6 | 9 | BEARISH | -28.8 |
| EXETF Extendicare Inc. | $1.9B | 20.3 | 43.8 | 14.1 | 5.0 | 31.2 | 3 | BEARISH | 74.0 |
| ALHC Alignment Healthcare, Inc. | $1.7B | 40.0 | 20.0 | -54.4 | 2.7 | 37.2 | 8 | BEARISH | -54.0 |
| TKNO Alpha Teknova, Inc. | $340M | -22.4 | -24.2 | -17.2 | -26.0 | 12.3 | 4 | BEARISH | 25.2 |
| HNSBF Hansa Biopharma AB (publ) | $330M | -4.6 | 159.8 | 1182.7 | -541.7 | -3.7 | 2 | BEARISH | -28.2 |
| VOGX Vogenx Inc. | $260M | — | — | — | — | — | — | BEARISH | — |
| PCVX Vaxcyte, Inc. | $9.5B | -8.0 | -36.5 | -66.4 | — | — | 0 | BEARISH | 43.7 |
| IDRSF Idorsia Ltd | $1.4B | -3.5 | 27.1 | -344.5 | -203.1 | -8.1 | 1 | BEARISH | 19.6 |
| VBIZF Viva Biotech Holdings | $400M | 13.1 | 4.5 | 4.2 | 8.0 | 2.9 | 7 | BEARISH | -35.1 |
| RCKT Rocket Pharmaceuticals, Inc. | $250M | -15.5 | -4.8 | -137.8 | — | — | 3 | BEARISH | -36.4 |
| DNLI Denali Therapeutics Inc. | $2.9B | -6.7 | -54.9 | -281.7 | -3539.2 | — | 3 | BEARISH | 20.4 |
| CRVS Corvus Pharmaceuticals, Inc. | $890M | -16.5 | -35.4 | -415.6 | — | — | 4 | BEARISH | 43.4 |
| SVRA Savara Inc. | $870M | -8.4 | -105.5 | -15438.9 | — | — | 2 | BEARISH | 11.5 |
| IMRX Immuneering Corporation | $240M | -3.7 | -52.1 | -112.8 | — | — | 4 | BEARISH | -36.6 |
| ARWR Arrowhead Pharmaceuticals, Inc. | $8.2B | -26.6 | -64.8 | 65.7 | -258.2 | 12.2 | 4 | BEARISH | 55.3 |
| IONS Ionis Pharmaceuticals, Inc. | $7.1B | -12.7 | -105.4 | -58.5 | -42.8 | -7.4 | 3 | BEARISH | -38.0 |
| PTCT PTC Therapeutics, Inc. | $5.1B | -126.1 | 20.6 | -5.4 | 23.2 | -42.8 | 2 | BEARISH | -6.5 |
| GALNF Galenica AG | $5.0B | 27.6 | 11.2 | 6.8 | 3.1 | 6.2 | 4 | BEARISH | 32.2 |
| INDV Indivior Pharmaceuticals Inc | $4.3B | 12.1 | -152.4 | 528.3 | 35.6 | 13.5 | 4 | BEARISH | 38.2 |
| AMLX Amylyx Pharmaceuticals, Inc. | $3.4B | -19.9 | -74.7 | 2020.5 | — | 100.0 | 5 | BEARISH | 99.7 |
| MBX MBX Biosciences, Inc. Common Stock | $2.3B | -22.1 | -33.2 | 1634.0 | — | — | 2 | BEARISH | 211.6 |
| VERA Vera Therapeutics, Inc. | $2.0B | -5.1 | -91.8 | 2030.6 | — | — | 1 | BEARISH | 2.6 |
| ANIP ANI Pharmaceuticals, Inc. | $1.7B | 14.8 | 20.0 | 20.7 | 9.3 | 30.9 | 7 | BEARISH | -24.5 |
| IMTX Immatics N.V. | $1.1B | -4.1 | -47.8 | -858.3 | -683.4 | -68.0 | 2 | BEARISH | -28.7 |
| KURA Kura Oncology, Inc. | $850M | -2.9 | -167.7 | 56.3 | -327.3 | -7.3 | 1 | BEARISH | 2.1 |
| ATTO Attovia Therapeutics, Inc. | $630M | -15.3 | -294.4 | -1137.2 | -4597.1 | -50.5 | 4 | BEARISH | 272.2 |
| OCS Oculis Holding AG | $490M | -4.7 | -44.0 | -31.0 | — | -6.9 | 3 | BEARISH | -63.1 |
| RADLY Raia Drogasil S.A. | $7.2B | 20.7 | 19.4 | 16.9 | 3.8 | 10.9 | 7 | BEARISH | -17.4 |
| WHTCF WELL Health Technologies Corp. | $770M | 165.0 | 0.5 | 5.4 | -2.7 | 38.6 | 6 | BEARISH | -17.4 |
| GNMLF Genomma Lab Internacional, S.A.B. de C.V. | $710M | 9.0 | 14.3 | 13.4 | 11.4 | 22.0 | 4 | BEARISH | -22.7 |
| AURA Aura Biosciences, Inc. | $650M | -3.5 | -53.5 | -1360.0 | — | — | 4 | BEARISH | 7.5 |
| SENS Senseonics Holdings, Inc. | $400M | -3.7 | -118.2 | -901.4 | -253.4 | 79.0 | 3 | BEARISH | 18.8 |
| TTRX Turn Therapeutics Inc. | $310M | -36.1 | -952.4 | 115.0 | — | — | 2 | BEARISH | 105.1 |
| ARCT Arcturus Therapeutics Holdings Inc. | $280M | -3.4 | -46.3 | -2501.0 | -803.8 | -79.1 | 1 | BEARISH | 0.1 |
| SPHRY Starpharma Holdings Limited | $220M | -26.0 | -46.5 | -441.4 | -725.1 | 186.8 | 4 | BEARISH | 73.3 |
| DNTH Dianthus Therapeutics, Inc. | $4.3B | -610.5 | -4.1 | -60.1 | -6598.6 | -60.8 | 3 | BEARISH | 141.6 |
| GHRS GH Research PLC | $1.2B | -20.0 | -18.8 | 2015.5 | — | — | 2 | BEARISH | 43.5 |
| ABUS Arbutus Biopharma Corp | $830M | 5.4 | 89.6 | 86.7 | -507.2 | 1078.8 | 4 | BEARISH | -1.6 |
| QTTB Q32 Bio Inc. | $260M | 3.1 | 72.1 | 435.2 | — | — | 5 | BEARISH | 193.3 |
| GNNSF Genscript Biotech Corporation | $9.6B | -14.1 | -15.4 | 2.9 | -32.0 | 53.1 | 4 | BEARISH | 97.7 |
| HYPMY Hypera S.A. | $3.8B | 7.9 | 13.2 | 12.8 | 21.0 | 31.8 | 8 | BEARISH | -2.2 |
| ANL Adlai Nortye Ltd. | $560M | -5.5 | -22.4 | -317.5 | -36.3 | 223.4 | 4 | BEARISH | 549.1 |
| AUNA Auna S.A. | $380M | -17.4 | 0.8 | 4.5 | 2.4 | 9.2 | 7 | BEARISH | -21.1 |
| ARTV Artiva Biotherapeutics, Inc. | $300M | -1.3 | -36.6 | -954.6 | — | — | 3 | BEARISH | -21.1 |
| SMTI Sanara MedTech Inc. | $300M | -8.9 | -147.7 | 19.8 | -1.6 | 12.9 | 5 | BEARISH | 5.7 |
| PLX Protalix BioTherapeutics, Inc. | $210M | 10.5 | 31.2 | 47.1 | 19.0 | 30.1 | 5 | BEARISH | 7.2 |
| MMED MiniMed Group, Inc. | $5.2B | — | — | — | — | — | — | BEARISH | — |
| CMOPF Cosmo N.V. | $1.1B | -158.0 | -1.2 | -2.9 | -9.5 | -43.8 | 1 | BEARISH | -22.4 |
| CGON CG Oncology Inc. | $5.5B | -23.5 | -26.4 | -2066.1 | -6832.8 | 1030.3 | 3 | BEARISH | 44.1 |
| CRSP CRISPR Therapeutics AG | $4.8B | -10.7 | -26.1 | -253.2 | -895.3 | -62.7 | 3 | BEARISH | -23.9 |
| PBLS Parabilis Medicines, Inc. | $3.0B | — | — | — | — | — | — | BEARISH | — |
| SUPN Supernus Pharmaceuticals, Inc. | $2.4B | -21.2 | -10.5 | -12.6 | -26.6 | 24.9 | 3 | BEARISH | -22.5 |
| MLYS Mineralys Therapeutics, Inc. | $1.8B | -4.9 | -80.9 | 2274.6 | — | — | 2 | BEARISH | -47.0 |
| GENB Generate Biomedicines, Inc. | $1.6B | -7.9 | -28.2 | -175.0 | -1065.2 | — | 1 | BEARISH | — |
| CMPS COMPASS Pathways plc | $1.6B | -2.1 | -319.1 | 48.8 | — | — | 2 | BEARISH | 88.1 |
| NKTR Nektar Therapeutics | $1.1B | -5.7 | -35.8 | -29.2 | -401.0 | -27.2 | 3 | BEARISH | -36.8 |
| AVBP ArriVent BioPharma, Inc. | $1.0B | -4.1 | -53.1 | 2345.1 | — | — | 3 | BEARISH | -17.2 |
| ALMS Alumis Inc. | $880M | -1.8 | -93.6 | 2645.2 | -8557.2 | -63.1 | 2 | BEARISH | 47.2 |
| SANA Sana Biotechnology, Inc. | $700M | -3.2 | -152.9 | -242.3 | — | — | 3 | BEARISH | -55.8 |
| FULC Fulcrum Therapeutics, Inc. | $280M | -3.1 | -32.4 | 2389.1 | — | — | 4 | BEARISH | -59.9 |
| IPSC Century Therapeutics, Inc. | $260M | -1.4 | -49.7 | -60.0 | — | -100.0 | 2 | BEARISH | 151.2 |
| CAMRF Camurus AB | $3.7B | 58.2 | 15.8 | 89.3 | 34.3 | -0.2 | 6 | BEARISH | -10.3 |
| ORIC ORIC Pharmaceuticals, Inc. | $1.4B | -6.7 | -39.8 | -102.9 | — | — | 3 | BEARISH | -31.3 |
| KSPHF Kissei Pharmaceutical Co., Ltd. | $1.0B | 11.3 | 6.5 | -1.9 | 20.2 | 10.7 | 6 | BEARISH | -2.4 |
| IMVT Immunovant, Inc. | $5.9B | -10.2 | -80.1 | 707.5 | -2159.6 | — | 2 | BEARISH | 52.5 |
| HRMY Harmony Biosciences Holdings, Inc. | $2.1B | 12.0 | 20.5 | 35.7 | 28.9 | 24.3 | 5 | BEARISH | 25.4 |
| ANRO Alto Neuroscience, Inc. | $860M | -9.3 | -49.2 | -201.4 | — | — | 3 | BEARISH | 110.7 |
| DSGN Design Therapeutics, Inc. | $640M | -9.1 | -34.1 | 1787.8 | — | — | 1 | BEARISH | 85.5 |
| RCUS Arcus Biosciences, Inc. | $2.3B | -4.6 | -89.2 | 309.6 | -222.0 | -55.3 | 0 | BEARISH | 4.8 |
| SGIPF Sugi Holdings Co.,Ltd. | $1.8B | 15.5 | 10.0 | 11.6 | 2.2 | 46.6 | 7 | BEARISH | 0.9 |
| AUTL Autolus Therapeutics plc | $410M | -1.5 | -132.9 | 451.5 | -85.6 | 292.0 | 3 | BEARISH | 1.3 |
| AVLN Avalyn Pharma Inc. Common Stock | $1.1B | — | — | — | — | — | — | BEARISH | — |
| BCAX Bicara Therapeutics Inc. Common Stock | $1.1B | -5.6 | -41.0 | 583.9 | — | — | 2 | BEARISH | 2.0 |
| MNKD MannKind Corporation | $1.0B | -23.4 | 71.4 | 4.0 | -17.4 | 30.5 | 2 | BEARISH | -38.0 |
| GLUE Monte Rosa Therapeutics, Inc. | $920M | -4.8 | -42.7 | 149.9 | -483.9 | -83.9 | 3 | BEARISH | -4.3 |
| WVE Wave Life Sciences Ltd. | $630M | -3.2 | -80.0 | -1243.7 | -470.5 | -35.1 | 4 | BEARISH | -51.6 |
| LRMR Larimar Therapeutics, Inc. | $240M | -1.2 | -139.6 | 590.9 | — | — | 2 | BEARISH | -43.2 |
| KRYS Krystal Biotech, Inc. | $9.2B | 38.6 | 20.1 | 40.4 | 45.9 | 22.6 | 7 | BEARISH | 72.2 |
| NVCR Novocure Ltd | $1.7B | -11.2 | -43.2 | -93.1 | -8.5 | 11.0 | 6 | BEARISH | 6.3 |
| INVA Innoviva, Inc. | $1.5B | 4.3 | 36.7 | 15.0 | -69.8 | 19.8 | 7 | BEARISH | 18.2 |
| LTGO Latigo Biotherapeutics Inc. | $900M | — | — | — | — | — | — | BEARISH | — |
| MTLZF Metall Zug AG | $680M | -34.8 | -2.8 | -1.4 | -5.6 | -0.3 | 6 | BEARISH | 0.0 |
| ACHV Achieve Life Sciences, Inc. | $670M | -4.4 | -845.0 | 24.6 | — | — | 2 | BEARISH | 38.6 |
| HELP Helus Pharma Inc. | $630M | -2.6 | -56.3 | -143.0 | — | — | 2 | BEARISH | — |
| IRWD Ironwood Pharmaceuticals, Inc. | $570M | 4.4 | -55.3 | 93.9 | 45.4 | 26.2 | 7 | BEARISH | 111.5 |
| TECX Tectonic Therapeutic, Inc. | $390M | -4.5 | -33.8 | -6371.3 | — | — | 1 | BEARISH | 18.6 |
| EIKN Eikon Therapeutics, Inc. Common Stock | $390M | — | — | — | — | — | — | BEARISH | — |
| VRNO Verano Holdings Corp | $370M | -1.4 | -4.5 | 1.5 | -6.0 | — | 3 | BEARISH | — |
| CLVLF Clinuvel Pharmaceuticals Limited | $250M | 10.6 | 13.2 | 126.7 | 41.1 | -1.1 | 6 | BEARISH | -32.0 |
| RNAC Cartesian Therapeutics, Inc. | $190M | -1.1 | 241.0 | 37.3 | — | 44.0 | 2 | BEARISH | -29.5 |
| NAGE Niagen Bioscience Inc | $190M | 12.9 | 21.8 | 44.7 | 3.2 | 11.0 | 6 | BEARISH | -67.0 |
| NPRRF Nipro Corporation | $1.4B | — | — | — | — | — | — | BEARISH | 5.8 |
| IBRX ImmunityBio, Inc. | $8.7B | -8.8 | 122.7 | 33.7 | -449.6 | 192.9 | 4 | BEARISH | 249.4 |
| ETON Eton Pharmaceuticals, Inc. | $1.4B | 109.0 | 36.0 | 33.3 | 30.8 | 81.5 | 7 | BEARISH | 177.1 |
| DRTS Alpha Tau Medical Ltd | $1.2B | -13.0 | -141.7 | -17.1 | — | — | 3 | BEARISH | 219.4 |
| SLDB Solid Biosciences Inc. | $630M | -3.2 | -65.5 | -1012.6 | — | — | 3 | BEARISH | 10.1 |
| NWPHF Newron Pharmaceuticals S.p.A. | $410M | -6.7 | 83.9 | -32.1 | -513.4 | — | 1 | BEARISH | — |
| OLMA Olema Pharmaceuticals, Inc. | $560M | -3.3 | -52.7 | 585.3 | — | — | 2 | BEARISH | -12.3 |
| CBIO Crescent Biopharma, Inc. | $480M | -1.8 | -107.7 | 1928.6 | — | — | 5 | BEARISH | 4.6 |
| BWAY BrainsWay Ltd. | $440M | 47.1 | 13.0 | 31.1 | 15.8 | 32.3 | 5 | BEARISH | 38.3 |
| BLSM BlossomHill Therapeutics, Inc. | $430M | — | — | — | — | — | — | BEARISH | — |
| HIMS Hims & Hers Health, Inc. | $6.2B | -45.7 | -32.0 | -7.1 | -11.5 | 28.0 | 4 | BEARISH | -42.7 |
| RTEZ Rest Ez Inc. | $4.2B | — | — | — | — | — | — | BEARISH | 0.0 |
| TARS Tarsus Pharmaceuticals, Inc. | $3.2B | -65.1 | -13.7 | 268.1 | -10.7 | 105.2 | 5 | BEARISH | 7.1 |
| DMPHF Dermapharm Holding SE | $2.4B | 13.9 | 25.6 | 13.0 | 8.1 | 0.5 | 5 | BEARISH | 20.6 |
| BFLY Butterfly Network, Inc. | $1.8B | -25.4 | -35.5 | -74.8 | -39.6 | 28.1 | 4 | BEARISH | 231.8 |
| AAPG Ascentage Pharma Group International | $1.4B | -6.1 | -236.8 | -144.8 | -270.2 | 170.9 | 3 | BEARISH | -58.7 |
| OMER Omeros Corporation | $1.2B | 9.1 | -89.2 | 71.8 | 46.4 | — | 5 | BEARISH | 131.7 |
| ASCLF Ascletis Pharma Inc. | $770M | -7.8 | -28.4 | -7144.0 | — | -60.6 | 2 | BEARISH | -40.0 |
| NVCT Nuvectis Pharma, Inc. | $650M | -14.0 | -214.6 | 174.4 | — | — | 1 | BEARISH | 197.4 |
| FDMT 4D Molecular Therapeutics, Inc. | $600M | -4.3 | -43.3 | -182.0 | -1929.0 | 278712.1 | 4 | BEARISH | 5.5 |
| PHAT Phathom Pharmaceuticals, Inc. | $460M | -4.7 | 26.4 | 8.9 | -23.7 | 110.2 | 4 | BEARISH | -55.7 |
| EPRX Eupraxia Pharmaceuticals Inc. | $450M | -6.9 | -68.6 | 8742.2 | — | — | 3 | BEARISH | 29.4 |
| AGEN Agenus Inc. | $290M | 2.4 | -33.2 | -20.4 | -1.6 | 30.5 | 6 | BEARISH | 60.6 |
| GALT Galectin Therapeutics Inc. | $210M | -8.0 | 21.9 | 99.4 | — | — | 2 | BEARISH | -35.4 |
| BLTE Belite Bio, Inc | $5.9B | -52.9 | -20.8 | -11.5 | — | — | 3 | BEARISH | 57.0 |
| YPHDF Ypsomed Holding AG | $5.7B | 23.8 | 31.1 | 17.4 | 22.5 | -2.3 | 8 | BEARISH | -8.1 |
| VRBCF Virbac S.A. | $3.2B | 18.8 | 13.6 | 12.7 | 11.4 | 3.9 | 5 | BEARISH | 10.8 |
| MEDGF Medacta Group S.A. | $2.7B | 33.1 | 17.1 | 9.8 | 11.4 | 8.9 | 4 | BEARISH | 63.9 |
| ORPEF Emeis | $2.3B | -4.5 | -19.0 | 3.2 | -5.4 | 40.2 | 5 | BEARISH | 0.0 |
| CURLF Curaleaf Holdings, Inc. | $1.8B | -62.5 | -4.2 | 0.5 | 3.7 | 2.7 | 7 | BEARISH | -2.1 |
| NUVB Nuvation Bio Inc. | $1.6B | -10.3 | -47.8 | 70.2 | -198.3 | 1083.6 | 4 | BEARISH | -6.2 |
| NVAX Novavax, Inc. | $1.6B | -6.6 | 323.7 | 29.2 | -94.2 | -61.6 | 2 | BEARISH | 17.6 |
| MEDOF Medios AG | $1.3B | 23.5 | 2.1 | 2.8 | 0.6 | 10.0 | 6 | BEARISH | 0.0 |
| CSBTF Kuros Biosciences AG | $950M | 109.9 | 9.6 | 9.2 | 4.8 | 29.1 | 4 | BEARISH | -39.6 |
| MGTX MeiraGTx Holdings plc | $880M | 12.3 | 72.3 | 96.7 | 50.0 | 948.3 | 7 | BEARISH | 7.8 |
| INMD InMode Ltd. | $800M | 10.9 | 12.3 | 44.5 | 17.9 | -6.7 | 5 | BEARISH | -11.3 |
| LXRX Lexicon Pharmaceuticals, Inc. | $630M | -9.8 | -40.2 | -99.7 | -4591.8 | -29.0 | 3 | BEARISH | 24.4 |
| CLYM Climb Bio, Inc. | $590M | -11.6 | -27.1 | -88.6 | — | — | 2 | BEARISH | 380.9 |
| AVR Anteris Technologies Global Corp. | $570M | -2.2 | -75.1 | 3136.2 | -2884.3 | 31.1 | 5 | BEARISH | 20.0 |
| MNPR Monopar Therapeutics Inc. | $470M | -30.7 | -19.5 | 523.8 | — | — | 2 | BEARISH | -11.9 |
| AVIR Atea Pharmaceuticals, Inc. | $320M | -2.0 | -58.1 | 974.6 | — | — | 3 | BEARISH | 29.9 |
| CYTK Cytokinetics, Incorporated | $8.5B | -8.5 | 329.8 | 811.2 | -622.8 | -17.2 | 2 | BEARISH | 6.4 |
| NAMS NewAmsterdam Pharma Company N.V. | $2.3B | -9.4 | -36.8 | 8216.2 | -1732.9 | -88.9 | 2 | BEARISH | -42.6 |
| HBMHF HBM Holdings Limited | $1.3B | 12.5 | 24.1 | 53.0 | 53.0 | 54.6 | 4 | BEARISH | -38.1 |
| RAFLF Raffles Medical Group Ltd | $1.2B | 22.0 | 5.8 | 7.3 | 8.2 | -2.8 | 7 | BEARISH | -20.0 |
| MCRPF MicroPort Scientific Corp. | $1.1B | 31.2 | 6.1 | -1.7 | 21.3 | -3.5 | 5 | BEARISH | -63.2 |
| EBOSY EBOS Group Limited | $1.0B | 15.3 | 5.0 | 4.4 | 1.7 | -8.1 | 6 | BEARISH | -47.5 |
| GERN Geron Corporation | $720M | -11.5 | -29.2 | -74.1 | -29.0 | 24.4 | 2 | BEARISH | -7.3 |
| XVIPY Xvivo Perfusion AB (publ) | $690M | 49.4 | 5.9 | 4.6 | 17.7 | 17.5 | 6 | BEARISH | — |
| SLBT SL Science Holding Ltd | $640M | — | — | — | — | — | — | BEARISH | — |
| GYRE Gyre Therapeutics, Inc. | $620M | -32.8 | -15.6 | -22.3 | -36.4 | 16.8 | 3 | BEARISH | -20.1 |
| ANNX Annexon, Inc. | $610M | -3.2 | -105.3 | -11323.3 | — | — | 2 | BEARISH | 17.1 |
| AGMB AgomAb Therapeutics N.V. American Depositary Shares | $450M | — | — | — | — | — | — | BEARISH | — |
| SSII SS Innovations International, Inc. | $450M | -39.0 | -26.1 | -15.6 | -19.1 | 108.5 | 3 | BEARISH | -72.1 |
| ASMB Assembly Biosciences, Inc. | $400M | 37.0 | -0.0 | 56.2 | -28.8 | 125.1 | 4 | BEARISH | -30.6 |
| SWDCF Swedencare AB (publ) | $370M | 35.2 | 1.2 | 1.7 | 3.9 | 1.4 | 7 | BEARISH | -46.5 |
| RLMD Relmada Therapeutics, Inc. | $350M | -3.5 | -55.7 | 460.5 | — | — | 3 | BEARISH | 52.9 |
| MPLT MapLight Therapeutics, Inc. | $340M | -1.6 | -57.5 | -366.6 | — | — | 2 | BEARISH | — |
| CTNM Contineum Therapeutics, Inc. | $270M | -5.2 | -28.0 | -541.6 | — | — | 4 | BEARISH | -18.6 |
| LXEO Lexeo Therapeutics, Inc. Common Stock | $230M | -2.5 | -46.8 | -249.1 | — | — | 3 | BEARISH | -68.9 |
| BOVNF BioInvent International AB (publ) | $220M | -2.8 | -88.2 | 20101.5 | -964.0 | -87.2 | 1 | BEARISH | 0.0 |
| BBOT BridgeBio Oncology Therapeutics Inc. | $210M | -0.0 | -56.4 | -157.3 | — | — | 1 | BEARISH | -75.5 |
| NHC National HealthCare Corporation | $3.7B | 23.5 | 13.1 | 12.6 | 9.9 | 6.9 | 8 | BEARISH | 72.6 |
| IDYA IDEAYA Biosciences, Inc. | $3.4B | -17.4 | -16.2 | -42.9 | -1269.6 | 3244.7 | 4 | BEARISH | 14.8 |
| TLX Telix Pharmaceuticals Limited | $3.1B | 92.5 | 8.6 | -1.0 | 8.0 | 10.5 | 4 | BEARISH | -16.5 |
| PGEN Precigen, Inc. | $2.2B | -5.4 | -4640.4 | -30.1 | 36.5 | 1875.0 | 5 | BEARISH | 42.0 |
| IRMD IRadimed Corporation | $1.1B | 46.0 | 23.5 | 50.1 | 25.5 | 11.2 | 6 | BEARISH | 7.8 |
| ZVRA Zevra Therapeutics, Inc. | $580M | 10.5 | 34.8 | -1356.4 | 22.1 | 119.4 | 6 | BEARISH | -5.2 |
| AQST Aquestive Therapeutics, Inc. | $500M | -6.2 | 121.1 | 43.4 | -165.5 | 22.6 | 5 | BEARISH | -40.5 |
| IRD Opus Genetics, Inc. | $290M | -2.7 | -4796.5 | 59.8 | -1072.6 | -36.1 | 3 | BEARISH | 73.9 |
| CORT Corcept Therapeutics Incorporated | $9.3B | 168.0 | 8.1 | 3.1 | 16.5 | 16.0 | 6 | BEARISH | 20.8 |
| RMYHY Ramsay Health Care Limited | $9.2B | 40.8 | 6.6 | 4.2 | 1.8 | 4.2 | 7 | BEARISH | 85.2 |
| TVTX Travere Therapeutics, Inc. | $4.7B | -112.6 | -151.8 | -21.0 | -20.5 | 77.1 | 6 | BEARISH | 81.3 |
| HAWPY Haw Par Corporation Limited | $3.0B | 12.3 | 5.2 | 1.6 | 93.0 | -12.8 | 4 | BEARISH | -20.4 |
| CHSYF China Medical System Holdings Limited | $2.7B | 13.6 | 8.6 | 9.0 | 21.9 | 9.2 | 4 | BEARISH | -17.8 |
| ARSUF Fagron N.V. | $2.0B | 18.9 | 16.7 | 10.8 | 8.4 | 11.8 | 4 | BEARISH | 9.8 |
| URGN UroGen Pharma Ltd. | $1.7B | -17.2 | 86.5 | 119.0 | -19.8 | 169.5 | 2 | BEARISH | 78.8 |
| SNDA Sonida Senior Living, Inc. | $1.6B | -5.3 | -25.2 | -2.9 | -11.8 | 49.4 | 4 | BEARISH | 23.9 |
| ELEAF EL.En. S.p.A. | $1.4B | 13.7 | 13.2 | 29.1 | 6.0 | 25.8 | 8 | BEARISH | 37.9 |
| MDCLF MedinCell S.A. | $1.1B | -29.2 | 472.2 | 81.6 | -152.1 | -14.8 | 3 | BEARISH | 333.5 |
| IART Integra LifeSciences Holdings Corporation | $930M | 70.5 | 1.2 | 13.4 | 3.6 | 0.8 | 6 | BEARISH | -25.6 |
| IMMX Immix Biopharma, Inc. | $680M | -9.3 | -34.2 | 1509.2 | — | — | 4 | BEARISH | 123.0 |
| CADL Candel Therapeutics, Inc. | $610M | -5.9 | -81.8 | 219.4 | — | — | 2 | BEARISH | 52.8 |
| GNFTF Genfit S.A. | $470M | -5.2 | -5084.0 | -322.7 | -124.0 | 27.5 | 3 | BEARISH | 153.5 |
| VREOF Vireo Growth Inc. | $310M | -4.1 | -4.6 | -0.7 | -0.0 | — | 3 | BEARISH | — |
| IKT Inhibikase Therapeutics, Inc. | $220M | -3.3 | -52.0 | 920.5 | — | — | 3 | BEARISH | 1.9 |
| REGMF RemeGen Co., Ltd. | $5.6B | 9.1 | 108.3 | 139.6 | 83.4 | 283.6 | 7 | BEARISH | -7.7 |
| LABFF Laboratorios Farmaceuticos Rovi, S.A. | $3.4B | 17.1 | 29.3 | 19.6 | 39.1 | 3.3 | 6 | BEARISH | -25.9 |
| AMFPF Amplifon S.p.A. | $3.0B | 42.8 | 5.7 | 7.2 | 6.4 | -0.2 | 5 | BEARISH | -36.0 |
| BKD Brookdale Senior Living Inc. | $2.4B | -16.5 | -362.1 | 10.3 | 3.2 | -2.3 | 6 | BEARISH | 7.7 |
| ADDLF AddLife AB (publ) | $1.9B | 34.5 | 11.3 | 7.0 | 4.9 | 1.1 | 4 | BEARISH | -62.5 |
| GENSF Genus plc | $1.8B | 5.4 | 45.4 | 9.0 | 80.4 | -3.8 | 5 | BEARISH | -19.4 |
| VIMGF Vimian Group AB (publ) | $1.5B | 48.7 | 5.4 | 6.4 | 7.4 | 8.9 | 7 | BEARISH | -8.0 |
| OCUL Ocular Therapeutix, Inc. | $1.4B | -4.7 | -73.0 | -31671.3 | -584.5 | -8.1 | 3 | BEARISH | -41.5 |
| GTBIF Green Thumb Industries Inc. | $1.4B | 11.8 | 7.0 | 2.5 | 1.6 | 4.8 | 7 | BEARISH | -16.3 |
| GPCR Structure Therapeutics Inc. | $1.2B | -7.1 | -20.2 | -1134.3 | — | — | 3 | BEARISH | -18.3 |
| SNDX Syndax Pharmaceuticals, Inc. | $1.2B | -5.4 | -255.9 | -270.9 | -67.8 | 222.3 | 4 | BEARISH | 1.2 |
| SHPHF Sihuan Pharmaceutical Holdings Group Ltd. | $1.1B | 18.6 | 5.7 | 8.4 | 19.4 | 24.4 | 6 | BEARISH | 20.0 |
| AKTS Aktis Oncology, Inc. | $850M | -15.8 | -29.9 | 276.4 | -713.5 | -36.1 | 5 | BEARISH | 373763.6 |
| CHIZF China Traditional Chinese Medicine Holdings Co. Limited | $820M | -4.8 | -4.9 | 0.0 | -14.3 | 5.6 | 6 | BEARISH | -40.3 |
| ARDX Ardelyx, Inc. | $770M | -13.2 | -38.6 | -22.7 | -13.8 | 16.8 | 4 | BEARISH | -40.5 |
| TGRNF Tong Ren Tang Technologies Co. Ltd. | $660M | 10.8 | 4.1 | 12.2 | 8.2 | -18.2 | 6 | BEARISH | -43.0 |
| CRWRF Craneware plc | $620M | 25.9 | 6.0 | 6.8 | 9.7 | 4.2 | 7 | BEARISH | -43.9 |
| EVOTF Evotec SE | $590M | -2.6 | -26.1 | -14.9 | -32.5 | -7.7 | 2 | BEARISH | -54.3 |
| CTMX CytomX Therapeutics, Inc. | $510M | -5.2 | -37.8 | 305.9 | -1457.4 | -87.0 | 2 | BEARISH | -29.1 |
| KSRBF Kossan Rubber Industries Bhd | $480M | 16.9 | 5.0 | 8.5 | 11.3 | 1.0 | 5 | BEARISH | -43.2 |
| PROK ProKidney Corp. | $470M | -2.7 | 9.2 | 13.2 | -18948.0 | 55.2 | 1 | BEARISH | -52.5 |
| FTH Faeth Therapeutics, Inc. | $440M | — | — | — | — | — | — | BEARISH | — |
| ALLO Allogene Therapeutics, Inc. | $430M | -1.9 | -42.4 | -81.9 | -919.8 | — | 5 | BEARISH | 2.5 |
| AVCTF Avacta Group Plc | $420M | -6.7 | -2083.2 | -753.6 | -33970.3 | -99.7 | 5 | BEARISH | -18.7 |
| SPRY ARS Pharmaceuticals, Inc. | $400M | -1.7 | -210.3 | -424.3 | -185.2 | 4.1 | 2 | BEARISH | -59.1 |
| CAPR Capricor Therapeutics, Inc. | $340M | -2.5 | -73.7 | -107.5 | — | -100.0 | 3 | BEARISH | -1.6 |
| KYTX Kyverna Therapeutics, Inc. | $330M | -1.9 | -87.2 | 14267.8 | — | — | 2 | BEARISH | -24.3 |
| SPHDF Santhera Pharmaceuticals Holding AG | $280M | -6.6 | 729.6 | 111.3 | -44.5 | 106.3 | 7 | BEARISH | 49.1 |
| ORYZF Oryzon Genomics S.A. | $250M | -80.4 | -3.0 | -7.2 | -1.6 | 12.6 | 4 | BEARISH | -14.1 |
| OCGN Ocugen, Inc. | $250M | -2.9 | 1211.7 | 190.2 | -1671.8 | -3.7 | 2 | BEARISH | -52.4 |
| ABEO Abeona Therapeutics Inc. | $250M | -3.9 | -43.1 | -5983.3 | -177.4 | 6280.0 | 2 | BEARISH | -18.8 |
| VNDA Vanda Pharmaceuticals Inc. | $240M | -0.9 | -77.8 | -201.0 | -123.7 | 6.0 | 3 | BEARISH | -27.4 |
| HLOSF Healios K.K. | $240M | 56.3 | 3.7 | -129.2 | 17028.6 | -47.1 | 4 | BEARISH | -48.6 |
| IPHYF Innate Pharma S.A. | $210M | -2.5 | 267.9 | 119.2 | -343.8 | 32.0 | 3 | BEARISH | -24.5 |
| EVMN Evommune, Inc. | $190M | -1.5 | -29.6 | -82.4 | — | — | 2 | BEARISH | — |
| BIOA BioAge Labs Inc. | $190M | -2.3 | -28.2 | -142.3 | -1064.7 | 168.1 | 4 | BEARISH | -28.0 |
| AXSM Axsome Therapeutics, Inc. | $7.6B | -37.9 | -245.1 | 859.1 | -23.5 | 56.9 | 5 | BEARISH | 9.8 |
| SFOSF Shanghai Fosun Pharmaceutical (Group) Co., Ltd. | $5.8B | 17.8 | 10.7 | 6.3 | 8.4 | 53.9 | 7 | BEARISH | -34.2 |
| TRSBF 3SBio Inc. | $4.3B | 3.4 | 37.1 | 80.3 | 25.3 | 93.8 | 7 | BEARISH | -51.7 |
| VKTX Viking Therapeutics, Inc. | $3.1B | -5.3 | -88.9 | 495.6 | — | — | 1 | BEARISH | -27.7 |
| BRCTF BioArctic AB | $2.6B | 263.7 | 5.2 | 77.4 | -4.5 | -46.1 | 3 | BEARISH | -8.6 |
| TMDX TransMedics Group, Inc. | $2.5B | 15.8 | 36.3 | 18.7 | 7.7 | 25.8 | 3 | BEARISH | -46.6 |
| ZLDPF Zealand Pharma A/S | $2.4B | 5.8 | 16.3 | 57.2 | 87.2 | -49.2 | 3 | BEARISH | -54.1 |
| INCPF InnoCare Pharma Limited | $2.4B | 18.7 | 12.6 | 45.8 | 23.1 | 108.5 | 4 | BEARISH | -50.9 |
| ULIHF The United Laboratories International Holdings Limited | $1.9B | 20.5 | 3.3 | 4.4 | 5.6 | -16.6 | 4 | BEARISH | -49.9 |
| FDMDF 4DMedical Limited | $1.6B | -9.2 | -174.5 | 43.4 | -1194.8 | 20.5 | 3 | BEARISH | 94.2 |
| LFTSF LifeTech Scientific Corporation | $1.0B | 103.0 | 7.3 | 6.9 | -5.7 | 103.7 | 4 | BEARISH | -14.3 |
| TTALF Terveystalo Oyj | $910M | 13.3 | 10.3 | 6.3 | 2.1 | -8.7 | 4 | BEARISH | -44.5 |
| IVEVF Inventiva S.A. | $750M | -6.2 | -988.4 | -371.6 | -347346.6 | -99.7 | 3 | BEARISH | -22.8 |
| NNCSF Nanosonics Limited | $620M | 53.0 | 8.3 | 15.6 | 8.1 | 2.4 | 4 | BEARISH | -39.9 |
| RGNX REGENXBIO Inc. | $440M | -1.7 | -137.6 | -368.4 | 21.0 | 12.0 | 2 | BEARISH | -49.4 |
| CALZF PolyNovo Limited | $430M | 82.1 | 8.4 | 9.3 | 10.0 | 12.8 | 7 | BEARISH | -38.6 |
| ALT Altimmune, Inc. | $410M | -2.6 | -28.9 | -43.1 | — | 55.0 | 4 | BEARISH | -46.0 |
| NIKA Nika Pharmaceuticals Inc. | $370M | -4711.6 | 26.8 | 18.5 | — | 100.0 | 3 | BEARISH | 8.5 |
| AVTX Avalo Therapeutics, Inc. | $370M | -1.4 | -36.3 | -148.4 | — | -86.6 | 4 | BEARISH | -61.6 |
| TLRY Tilray Brands, Inc. | $310M | -2.0 | -8.8 | -3.4 | -16.8 | -16.9 | 3 | BEARISH | -81.4 |
| DMTRF 3-D Matrix, Ltd. | $310M | 11.9 | 75.0 | 31.1 | 9.4 | 57.0 | 6 | BEARISH | 61.3 |
| CABA Cabaletta Bio, Inc. | $250M | -0.9 | -93.2 | -1308.0 | — | — | 3 | BEARISH | -40.9 |
| SCTX Scribe Therapeutics Inc. | $250M | — | — | — | — | — | — | BEARISH | — |
| ACIU AC Immune S.A. | $250M | -4.2 | -78.5 | 96.7 | 12.4 | -39.5 | 2 | BEARISH | -30.8 |
| PALI Palisade Bio, Inc. | $230M | -2.3 | -51.4 | 815.6 | -2114.8 | — | 5 | BEARISH | -31.0 |
Profile Radar
Valuation vs Profitability
Performance Comparison
Industry Market Share
MDXG vs Benchmarks
ROIC
Gross Margin
Op Margin
Net Margin
Revenue Growth
P/E Ratio
ROE
Piotroski F